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Abstract 
Background and Purpose 
All types of physical activities are associated with some kind of health benefits. These 
include weight gain prevention, weight loss and weight regain prevention after weight loss 
and maintaining healthy body composition and fitness. However, the long term effects of 
exercise on energy homeostasis vary according to the exercise duration, mode, intensity and 
volume; and the characteristics of the participants studied and whether the exercise is 
accompanied with dietary restrictions. Therefore, the aim of this research was to determine 
the effects of 8-week supervised and structured exercise training programs – of different 
modes, intensities and volumes – on appetite and appetite-regulating gut hormones, as well as 
effects on body weight and waist circumference in overweight and obese adults. 
Methods  
A longitudinal randomised controlled pilot trial was conducted at the Boden Institute of 
Obesity, Nutrition, Exercise & Eating Disorders at the University of Sydney in the period 
September 2012 to November 2013. Twenty-eight eligible overweight and obese adults were 
randomly allocated to one of 4 intervention groups or a control group as follows: High-
intensity/low energy expenditure aerobic exercise training (HI:LO) (n=7), Low-intensity/high 
energy expenditure aerobic exercise training (LO:HI) (n=8), Low-intensity/low energy 
expenditure aerobic exercise training (LO:LO) (n=4), Progressive resistance training (PRT) 
(n=4), and the control group (n=5). Subjective appetite was assessed using the Electronic 
Appetite Ratings System (EARS), and the plasma concentrations of total ghrelin and peptide 
tyrosine tyrosine (PYY) hormones were assessed at baseline and after intervention in the 
fasted state; and anthropometric measurements were also recorded. Participants were not 
prescribed any dietary restriction and were asked not to change their usual diet. Statistical 
analyses were performed using SPSS. The baseline anthropometric measurements were 
analysed using ANOVA according to the type of exercise training intervention. For all other 
parameters, non-parametric tests were adopted. To test the significance of changes after 
intervention, a Paired Sample t test was used for continuous variables and a Wilcoxon signed-
rank test for non-parametric variables. P values of ≤ 0.05 were accepted as being statistically 
significant. 
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Results 
None of the exercise interventions had any effect on body mass index (BMI), but HI:LO and 
LO:HI resulted in statistically significant  reductions in waist circumference when comparing 
pre- to post-intervention values; however, this change was not statistically significant after 
adjusting for baseline values. There were no statistically significant differences in the 
subjective appetite responses among the studied groups, either pre- or post-intervention. 
Plasma ghrelin and PYY concentrations were associated with similar findings for subjective 
appetite, as there were no statistically significant changes after all interventions. 
Conclusions 
Eight weeks of different intensities and volumes of regular aerobic exercise and progressive 
resistance training did not significantly influence subjective appetite or the plasma levels of 
the gut-derived appetite-regulating hormones, total ghrelin and PYY in overweight and obese 
adults who participated in four interventional supervised programs. This result is contrary to 
what might have been expected from several acute studies, which showed an “acute exercise-
induced anorexia” effect. The “no change” effect of chronic exercise on appetite seen in this 
trial indicates the need for future studies that define the potential roles of different modes and 
intensities of chronic exercise in weight regain prevention programs, particularly in those 
subjects on diet-induced weight loss program who have persistent changes in appetite that 
may ultimately stimulate food intake and obesity relapse. 
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1 Introduction 
1.1 Obesity 
Overweight and obesity are conditions in which excess body fat accumulates in adipose 
tissue depots around the body and impairs health [1-4]. The distribution of this additional fat 
varies between men and women: in men, fat mainly accumulates around the waist (android 
distribution), and in women it accumulates around the buttocks (gynoid distribution) [4]. 
Various methods to measure body fatness have been used including cadaver analysis, 
computed tomography (CT), magnetic resonance imaging (MRI), dual-energy X-Ray 
abosorptiometry, bioimpedance analysis and body mass index (BMI) [4]. However, the most 
widely used index of obesity is BMI, which is calculated by body weight in kilograms (kg) 
divided by height in square meters (m2), BMI = kg/m2.  The desirable or healthy BMI ranges 
between 18.5 to 24.9 kg/m2 [1].Overweight ranges between BMI of 25 to 29.9 kg/m2, and a 
BMI equal or above 30 kg/m2 is defined as obesity [1, 4].  
1.1.1 World overweight and obesity prevalence rates 
The prevalence of obesity has doubled since 1980 [1]: between 1980 and 2008, worldwide 
mean BMI increased by 0·4 kg/m2 and 0.5 kg/m2 per decade for men and women, 
respectively [5]. In 2008, the World Health Organisation (WHO) estimated that more than 1.4 
billion adults aged 20 and older were overweight; and of these, over 200 million men and 
nearly 300 million women were obese [1]. It is in fact estimated that more than one in ten of 
the world’s adult population is obese [1]. Among the high-income countries, people in the 
United States had the highest mean BMI [5]. In 2007-2008, 68% of Americans were 
overweight or obese and approximately 34% were obese [2]. Similarly high rates of 
overweight and obesity were reported in Oceanic countries [5]: both female and male BMIs 
increased to 33·9 kg/m2 (32·8—35·0) for men and 35·0 kg/m2 (33·6—36·3) for women in 
Nauru in 2008 [5]. In nine Oceanic countries female BMI increased by more than 2.0 kg/m2 
per decade [5]. 
1.1.2 Australian overweight and obesity prevalence rates  
The prevalence of overweight and obesity has increased in Australia, from 56.3% in 1995 to 
61.2% in 2007–08 [6]. In the 2011-2012 National Australian Health survey, about  (63.4%) 
of adult Australians were overweight (35.0%) or obese (28.3%) [6]. More males than females 
were overweight or obese – 70.3% and 56.2%, respectively [6]. 
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1.1.3 Diseases associated with obesity 
Overweight and obesity are associated with high rates of morbidity and mortality [2]. Raised 
BMI negatively affects most of the body systems and is related to several non-communicable 
diseases or states of greater health risk: e.g., type 2 diabetes, dyslipidaemia, coronary artery 
diseases, hypertension, sleep apnoea, cognitive dysfunction, non-alcoholic fatty liver, and 
some malignancies such as breast, colon and prostate cancer [1, 2]. WHO records indicate 
that overweight and obesity are the fifth leading cause of death worldwide, and 2.8 million 
adults die annually as a direct result of overweight and obesity [1].   
1.1.4 Obesity prevention 
The increasing prevalence of overweight and obesity indicates the need for improving current 
intervention strategies. Several types of interventions for obesity management have been 
used, including healthy diet, regular exercise, behavioural modification, pharmacological 
treatment and bariatric surgery [3]. Among all the interventions, bariatric surgery provides 
substantial and sustained weight loss compared to the other conventional interventions. In the 
large majority of cases (>90%), bariatric surgery is effective, safe, and well tolerated [7]. 
Data suggest that gastric bypass surgery results in greater weight loss than other procedures; 
but this is based on a very limited number of trials, and there are still safety and cost concerns 
regarding it in comparison with the others [8]. 
Lifestyle programs are multifactorial interventions tailored to the needs of an 
individual or of a group of subjects according to their risk factors status [3]. Lifestyle 
modification includes dietary modification and physical exercise [7]. However, food 
restriction alone may not solve the problem of excess weight unless it is accompanied by 
physical training [7]. Lifestyle modifications can be effective in the prevention and treatment 
of obesity in the mid- to long-term, leading to significant reductions in blood pressure, blood 
lipids and blood glucose levels [3].  
1.2 Exercise 
Physical activity (PA) is recommended as one of the important components of any weight 
management program that may also include energy restriction, pharmacological and surgical 
interventions. Physical activity in the context of weight management aims for weight gain 
prevention, weight loss, and the prevention of weight regain after weight loss [9-12]. These 
positive impacts are achieved fully or partially in all types of exercise, such as the 
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unstructured regular lifestyle activities and the structured exercises that include various forms 
of aerobic exercises (AE) and progressive resistance training (PRT) [12]. However, the extent 
of the influence of physical activity on body weight, metabolism and body fitness relates to 
the extent of reduction in energy intake [11], the mode and the intensity of exercise, which 
have dose-dependent effects [9]. The next section reviews the health benefits of physical 
activity, discusses the various types of exercise, and defines their various roles in weight loss, 
weight maintenance, body composition and fitness. It also discusses its benefits for some 
kinds of common chronic illnesses that relate to increasing body weight – namely, diabetes, 
hypertension and osteoarthritis. 
1.2.1 The health benefits of physical activity 
There is wealth of information available showing that increasing levels of all types of 
physical activities provide health benefits, which are attributed largely to the positive effects 
of physical activity on weight gain prevention, weight loss and prevention of weight regain 
after weight loss [9, 10, 13, 14]. No randomised controlled trials were published on physical 
activity as a cause of obesity, and there are significant scientific data to support a causative 
link between lack of physical activity and increasing BMI [10]. Other positive effects of 
various types of physical activity include effects on obesity-related chronic illnesses, such as 
atherosclerotic cardiovascular diseases [13], type 2 diabetes mellitus [15], hypertension [16], 
hyperlipidaemia [13], osteoarthritis [17] and some cancers [9, 10]. Moreover, exercise 
training improves body composition [16], cardio-respiratory fitness [18] and cardiovascular 
risk profile [13], and all translate to better health outcomes [15]; while other benefits include 
positive effects in managing asthmatics [9, 18]. Some of these health benefits are achieved 
independently of weight loss, and, perhaps, even if weight is gained [13]. Progressive 
resistance training has not traditionally been promoted in weight loss interventions, possibly 
because the energy expenditure associated with progressive resistance training is limited [13]. 
However, progressive resistance training may increase muscle mass, which may in turn 
increase 24-h energy expenditure [13].  
1.2.2 Types of physical activity  
Numerous categorizations of types of physical activity are used in the literature [13, 19], 
which leads to difficulties in assessing and comparing results of various physical activity 
studies [20]. So in this study, physical activities are categorized into two main types: 
unstructured lifestyle activities and structured exercises – the latter including various forms of 
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aerobic exercise and progressive resistance training.  Published data indicate that the intended 
effects of physical activity depend on sound understanding of the mode of exercise 
performed, and its intensity – as discussed below [20]. 
1.2.2.1  Lifestyle activities 
This term refers to all activities an individual performs in the course of daily life that can 
contribute to significant energy expenditure [21]. Lifestyle activities may be defined, 
therefore, as all forms of unstructured PA not intended to constitute part of structured 
exercise [13]. Levine et al. (2007) have developed the concept of non-exercise activity 
thermogenesis (NEAT) which they define as “all energy expenditure that is not from 
sleeping, eating, or planned exercise programs” [22]. Examples of these activities include 
occupational activity, commuting, work around the home and leisure activities [14]. Several 
methods have been used to measure this type of physical activity and its resultant energy 
expenditure, including subjective self-reported physical activity questionnaires such as the 
International Physical Activity Questionnaire IPAQ [23], and more objective measurements 
using pedometers, inclinometers, accelerometers, or doubly-labelled water assessments [14, 
20, 22, 24].  
Numerous studies have hypothesized that higher levels of lifestyle activity prevent 
initial weight gain as well as assisting in weight loss and weight loss maintenance after 
weight loss [14]. A systematic review of the literature shows that an increase in the number 
of steps walked by 2100 per day, as measured by a pedometer, can decrease BMI by a modest 
yet significant 0.38 kg/m2 [21]. However, methodologies of numerous studies conducted on 
lifestyle physical activity are inconsistent; because researchers use a wide variety of 
assessment methods, diverse populations and are without clear definitions of lifestyle 
physical activity [12]. Despite these limitations of published studies and the reported modest 
effect of lifestyle physical activity, it is reasonable to recommend its increase as a strategy for 
weight management [12]. 
1.2.2.2  Structured exercises 
The lack of precise definition of lifestyle physical activity and its modest effects indicates the 
need for more planned, supervised and structured types of physical activity. In this regard, the 
scientific literature refers to two main categories of structured physical activity, namely: 
1. aerobic exercise that includes aquatic physical activity; and  
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2. progressive resistance training.  
Each type has relatively different goals and benefits, as outlined later in this section [12, 19]. 
According to the Australian National Health Survey (2012), 74% of respondents reported that 
they were not involved in any type of structured physical activity [6].   
1.2.2.2.1 Aerobic exercise  
Aerobic exercise is any brisk exercise that increases the circulation of oxygen and is 
accompanied by increased breathing rates [12]. Forms of aerobic exercise include walking, 
jogging, running, cycling, swimming and some endurance game activities: in all, large 
muscle groups are utilized in a rhythmic fashion [18]. Benefits of aerobic exercise include 
reduced risk of acute coronary ischaemia, of stroke and of overall cardiovascular mortality, as 
well as improved blood lipid profiles, blood pressure and inflammatory markers [25]. Aquatic 
exercise has been recommended as a more comfortable form of physical activity for 
overweight or obese individuals who have potential functional limitations [9]. One of the few 
studies published in this area aimed to assess the effects of combined supervised aquatic-
exercise and walking compared to walking alone on the body weight of 44 obese women over 
a 16-week period. The study suggested that aquatic exercise in combination with walking can 
improve functional status and is a better alternative than walking alone for overweight 
women [26].  
1.2.2.2.2  Progressive resistance training  
‘Resistance training’ or ‘progressive resistance training’ refers to all forms of training that 
cause muscles to contract against resistance, thus aiming to increase muscle strength, mass, 
tone and/or endurance [27]. Progressive resistance training is well known as an effective 
method for developing musculoskeletal strength, muscular fitness, and the prevention as well 
as the rehabilitation of musculoskeletal injuries [20, 28]. In progressive resistance training, 
multi joints and large muscle groups are involved in rhythmic fashion [19]; and training 
programs usually consist of working on all the major muscle groups in order to strengthen 
them [19] (in older adults, it is advised that these training programs should focus on multi-
joint exercises [27]). Progressive resistance training usually stimulates skeletal muscles to 
synthesize new muscle protein and undergo hypertrophy [19]: to improve its effects on 
increasing muscle mass, it is recommended to do 1-2 sets of 8 to 12 repetitions per set with 
an intensity more than 60% of 1-repetition maximum (1RM), with 8 to 10 exercises per 
session and 2-3 sessions weekly [20, 28]. Evidence suggests that maintenance of a large lean 
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body mass may decrease metabolic risk factors or disease including obesity, type 2 diabetes 
mellitus and dyslipidaemia [15, 19]. In addition to the muscular benefits of progressive 
resistance training, it can improve insulin-stimulated glucose uptake, may be an alternative to 
aerobic exercise in modifying metabolic risk factors [29], and may increase bone mineral 
density [30]. However, further evidence is needed to support the potential benefit of 
progressive resistance training in weight loss and weight management [12, 19]. 
1.2.3 Benefits of physical activity for weight loss and 
subsequent weight maintenance 
Available data support the benefits of increasing daily activity in prevention of the global 
epidemic of obesity. The benefits on long-term weight loss have been reported in overweight 
individuals, in patients with severe obesity (BMI ≥ 35kg/m2), and even in patients who have 
undergone bariatric surgery [9]. Physical activity seems to be an important component of 
lifestyle interventions for weight loss and maintenance. The 2009 stand of the American 
College of Sports Medicine [12] stresses the importance of increasing the levels of physical 
activity for better weight loss and preventing weight regain after weight loss [13, 14].  
1.2.3.1  Benefits of physical activity on weight gain prevention 
in non-obese  
Evidence is accumulating regarding the role of an active lifestyle in prevention of substantial 
weight gain and obesity with age; but also indicating early promotion of physical activity in 
non-obese adults who aim to maintain their normal weight throughout life [31]. In the 
consensus statement of the American College of Sports Medicine, researchers indicated a 
moderately strong relationship between the risk of developing obesity and decreasing levels 
of physical activity [32]. Furthermore, another prospective study conducted on 6223 men and 
women indicated a positive relationship between increasing physical activity duration and 
weight maintenance in a study group that had weight, peak VO2, and other parameters 
measured at each of three visits.  The study reported that for each 1-minute improvement in 
exercise on the treadmill – as an indication of increased physical activity and fitness – there 
was 21% reduction in the odds of gaining 10 kg or more in both sexes over the 7.5 years 
study period [31].  
According to the most recent stand by the American College of Sports Medicine, it is 
now evident that physical activity of 150 to 250 min.wk-1 with an energy equivalent of 1200 
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to 2000 min.wk-1 (e.g., brisk walking of approximately 20-32 kilometres per week) is 
effective to prevent weight gain greater than 30% in most adults [13]. 
1.2.3.2 Benefits of physical activity on weight loss  
It is already evident that a negative energy balance generated by physical activity will result 
in weight loss, and this effect is greater the more the negative energy balance [13]. The earlier 
(2001) American College of Sports Medicine guidelines [14] indicate that a minimum of 150 
min.wk-1 of moderate intensity physical activity for overweight and obese adults is 
recommended for health improvement; however, for long-term weight loss more physical 
activity is recommended – 200–300 min.wk-1 [14]. The updated guidelines from 2009 [13] 
indicate that 150 min.wk-1 physical activity promotes only initial minimal weight loss and 
stresses greater amounts of physical activity (more than 250 min.wk-1) being needed to 
achieve clinically significant weight loss [13]. It also indicates a dose-response relationship 
between physical activity and loss of weight, as physical activity of >150 min.wk-1 results in 
modest losses of 2 to 3 kg, whereas >225–420 min.wk-1 results in losses of 5 to 7.5 kg over a 
year [13]. Thus, higher doses of physical activity may provide a loss of 3% or more of initial 
weight [13]. 
The effects of physical activity on body weight depend not only on the duration, but 
also on the intensity of the physical activity [9, 13, 19]. Intensity is usually measured by a 
unit termed ‘Metabolic Equivalent’ (MET), which describes the energy expenditure of a 
certain activity where 1 MET equals 3.5ml O2/kg/min [33]. For example, a 4 MET activity 
expends 4 times the energy used by the body fat at rest (1MET), and so on [33]. According to 
the Physical Activity Guidelines for Americans [33], light intensity is defined as 1.1 to 2.9 
METs, moderate intensity activity is 3.0 to 5.9 METs, and vigorous activity is 6 METs or 
more [33]. For example, walking at 4.8 kilometers per hour requires 3.3 METs of energy 
expenditure and is therefore considered a moderate intensity exercise.  
Conflicting findings are reported on the effects of physical activity on weight loss in 
both sexes [13, 34, 35]. In a randomised controlled trial over 16 months, involving 225 min. 
of moderate intensity physical activity per week, Donnelly et al. (2003) find a minimal but 
significant difference of 0.4 kg between males and females in favor of men, who lost 5.2 kg 
versus the women, who lost 4.8 kg compared with controls [34]. However, Stefanick et al. 
(1998) have not found any similar gender difference [35]. 
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When it comes to the mode of exercise in weight loss, most studies focus on the role 
of various forms of aerobic exercise rather than on progressive resistance training [10], 
although it is now evident that the latter is associated with loss of fat mass and increase of fat-
free mass, as well as decreasing health risks [13, 19]. Evidence also indicates that progressive 
resistance training even without concomitant weight loss may reduce health risks and 
improve metabolic factors in overweight and obese subjects [16]. These modifications 
include positive effects on blood lipids profiles [36], improving insulin sensitivity [37], 
decreasing glycosylated haemoglobin HbA1c [38] and reducing glucose-stimulated 
circulating insulin concentrations [13, 19]. All of these effects may lead to reduction in the 
complications of metabolic disorders [19]. 
However, physical activities alone may not be sufficient to promote weight loss, 
unless accompanied by energy restriction. Studies that investigate the chronic effects of 
different doses of exercise on weight change in adults without associated reduction of energy 
intake are few. In this regard, Jakicic et al. (2011) study the effect of different intensities of 
physical activity (moderate PA, high PA and a self-help control group) on weight change in 
278 overweight adults, with no reduction of energy intake, over 18 months: participants who 
reduce their body weight by more than 3% increase physical activity by 162 minutes per 
week above baseline levels, compared with only 78.2 and 74.7 minutes per week in those 
participants who maintain their body weight within 3% of their initial weight or gain more 
than 3%, respectively [39]. When physical activity is added to the energy-restricted diet, the 
resultant weight loss after 6 months is 8.2 kg, which improves by 25% to 10.9 kg after 
combining both strategies in 130 severely obese subjects  [40]. This effect of PA to enhance 
weight loss is greater when moderate, compared with severe dietary restriction [40]; possibly 
because the metabolic adaptations to severe energy restriction [41] may prevent any further 
benefit from physical activity on weight loss. In any case, these studies demonstrate overall 
the importance of adding physical activity programs to any dietary restriction program to 
maximize weight loss and improve the related health benefits [13].  
Increasing the levels of physical activity and other behavioral therapies such as self-
monitoring, goal-setting, problem-solving, meal replacements and food provision [42] are 
recommended in conjunction, also, with pharmacological and surgical interventions for 
further weight loss and weight maintenance as demonstrated in various studies [13, 14]. 
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Finally, it is already noticed that individual responses to exercise vary, as some people 
do not experience the beneficial effects of exercise on body weight [43]. This finding is 
explained based on the various compensatory behavioural and metabolic responses in some 
individuals, which include changes in feelings of hunger or fullness and associated changes in 
food intake [43]. This inter-individual variability in the effects of PA on body weight needs 
further research to identify those at risk of not benefiting and the reasons behind this 
drawback in some subjects [43]. Regardless of the variability in effects of physical activity on 
body weight, regular physical activity should be recommended as an important component of 
any weight loss program, due to other benefits to health and weight maintenance, as outlined 
below. 
1.2.3.3  Benefits of physical activity for weight maintenance   
Physical activities are crucial for primary prevention of weight gain, promotion of long-term 
weight loss and the prevention of weight regain after weight loss. The maintenance of an 
initially normal weight, not weight reduction, should be the primary goal for exercise, 
because weight loss in already overweight or obese individuals is notoriously difficult. In this 
regard, many studies invariably point to the role of regular physical activities as a cornerstone 
of primary prevention of excess weight in early life as well as for weight maintenance 
throughout life [10]. 
1.2.3.4  Benefits of physical activity on weight regain 
prevention in post-obese 
Physical activity is a critically important behavior for promoting long-term weight loss and 
prevention of weight regain [9]. Indeed, physical activity is often promoted as the best 
predictor of weight maintenance after weight loss [44, 45]. This observation is supported by 
the recommendations in 2009 of the American College of Sports Medicine, which 
recommends more than 250 minutes per week of physical activity for maintenance of lost 
weight [12]. It also indicates that several studies support the value of 300 minutes or more per 
week of physical activity to reduce weight regain [12] – which recommendation is consistent 
with earlier empirical studies [9]. However, the positive effects of physical activity on weight 
maintenance are reported largely in cross-sectional and prospective studies but not in well-
designed randomised controlled trials [12]. Several studies indicate that the long-term effect 
of physical activity on prevention of weight regain is better when physical activity is 
accompanied by dietary restriction and behavioural changes, as almost  of those who have 
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lost weight regain the initial weight within one year [46]. Interestingly, physical activity is 
also recommended in post-bariatric surgery patients to prevent weight regain. In this regard, 
greater weight loss has been reported at 6 and 12 months after obesity surgery amongst 
patients who participated in 150 minutes or more of exercise per week, compared with those 
participating for fewer than 150 minutes per week [47]. Overall, these data demonstrate the 
importance of physical activity for preventing weight regain after a variety of weight loss 
interventions.  
1.2.3.5 Benefits of physical activity on body fitness and 
composition 
To judge the effectiveness of physical activity by its direct effect on the weighing scale is 
insufficient and possibly even misleading [10], as physical activity has many health benefits 
in addition to its major role in weigh management. Physical activity improves both body 
fitness and fatness (i.e., body composition) [9]. Benefits to body fitness are related to the 
positive effects of PA on the functions of several systems – e.g., the cardio-respiratory and 
musculoskeletal systems – in addition to its positive effects on various metabolic processes. 
The Aerobics Center Longitudinal Study and numerous other studies indicate that cardio-
respiratory fitness is a predictor of all-cause mortality and cardiovascular disease, 
independent of measures of body fatness [9]. Cumulative data in the literature suggest that 
physical activity improves cardio-reparatory functions in overweight and obese patients, and 
this is achieved regardless of whether weight is lost or not [9]. Similar positive effects were 
not observed when only dietary restriction was used. It has also been reported that improving 
fitness is associated with lower mortality rates, decreasing by 7.9% for each minute of 
improvement on a treadmill test [48]. Nocon et al. 2008 [49], systematically review 33 
studies that involve 883,372 participants, finding that the majority of studies report 
significant risk reduction of mortality in active subjects.  Physical activity is associated with 
marked risk reduction of cardiovascular mortality of 35% and all-cause mortality by 33%, 
even after adjusting for the other relevant risk factors in both men and women [49]. Available 
published data also suggest that both cardio-respiratory fitness and body fatness may 
influence selective risk factors for diabetes and cardiovascular disease [9, 19]. Therefore, 
interventions for overweight and obese adults that focus on both weight loss and 
improvements in cardio-respiratory fitness may provide the most significant improvements in 
health outcomes [9]. 
  22 
Besides benefits of fitness in reducing mortality rates, physical activity improves body 
composition: this effect varies according to the mode of physical activity used. For example, 
progressive resistance training increases fat-free mass when performed alone or in 
combination with dietary restriction [13]; and this effect also increases when combined with 
aerobic exercise, compared with progressive resistance training alone [9, 13]. The favourable 
effects of progressive resistance training with or without aerobic exercise on body fat 
distribution are described as changes in waist circumference, waist to hip ratio, and waist to 
thigh ratio in large observational studies [10]. Findings also demonstrate that progressive 
resistance training may be an effective alternative to improving body composition and 
maintaining reduced fat mass in obese patients, as it preferentially mobilises the visceral and 
subcutaneous adipose tissue in the abdominal region [19]. Recent data suggest that aerobic 
exercise is important in exercise programmes aimed at reducing visceral adipose tissue 
(VAT) [50]. 
1.2.4 Benefits to chronic illnesses of physical activity 
The benefits of physical activity in the management of several chronic illnesses – or what 
have been recently referred to as the “chronic diseases of physical inactivity” [51] – have 
already been acknowledged in the literature [12, 15-19]. The list of these illnesses is long, 
and most are related to the increasing body weight seen in inactive populations [9]. Health 
and fitness professionals should be aware of these benefits, and consider prescribing various 
types of physical activity for the affected patients [20].  
Next are discussed three of the common illnesses that may benefit from physical 
activity. 
1.2.4.1  Diabetes mellitus 
There is growing evidence that the increasing global prevalence rates of type 2 diabetes 
mellitus (T2DM) and pre-diabetes conditions (namely, impaired glucose tolerance and 
impaired fasting glucose) are linked to the steadily increasing rates of overweight and obesity 
[13, 15, 19]. This association has been attributed to recent changes in lifestyle, particularly 
lack of physical activity. Regular physical activity, in association with other lifestyle changes 
– dietary restriction – is effective in improving glycaemic control amongst people with  pre-
diabetes, as well as for the prevention and treatment of T2DM [15, 19]. In an observational 
study on 3,757 participants, standing or walking around the home for two hours daily was 
associated with a 9% and a 12% reduction in obesity and T2DM rates respectively, compared 
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with 24% and 34% reductions in obesity and T2DM rates respectively when brisk walking of 
one hour per day was performed [52]. In a more recent randomised controlled trial on a group 
of people with T2DM, Karstoft et al. (2012) report the importance of using physical activity 
in diabetics for improving physical fitness, body composition and glycaemic control [38]; so  
physical activity program should be a core component of any management plan for diabetic 
or pre-diabetic patients [15]. In this regard, and as with recommendations for the general, 
non-obese population, a minimum of 210 min per week of moderate intensity exercise, or 125 
min per week of vigorous intensity exercise with no more than two consecutive days without 
training, are recommended for both diabetic and pre-diabetic patients [15]. Two or more 
progressive resistance training sessions per week are also recommended, within the total 210 
or 125 min of moderate or vigorous exercise [15]. Ideally, the exercise should consist of a 
combination of some aerobic and some progressive resistance training; however, if only one 
modality is feasible, then either modality alone is effective [15, 19]. 
1.2.4.2  Hypertension 
High blood pressure or hypertension is a common clinical condition that is a leading 
contributor to premature death and cardiovascular co-morbidities [16]. Lifestyle modification 
including increasing physical activity is one of the important first-line treatments for 
hypertensive patients. Aerobic exercise is regarded as a first approach in the primary 
prevention and treatment of hypertension. In contrast, evidence is lacking for benefits of 
progressive resistance training in lowering high blood pressure [16, 19], although resistance 
training will still provide health benefits to this population (as to the general populace). 
Patients with hypertension will thus benefit from a mix of moderate to vigorous aerobic 
activity in addition to progressive resistance training [16]. However, patients should be 
cautious when they perform certain types of vigorous progressive resistance training – such 
as lifting heavy weights – as it may have a pressor effect on blood pressure [16]. 
1.2.4.3  Osteoarthritis 
Osteoarthritis is a chronic joint disease that affects mainly the lower body joints, particularly 
the hip and knee joints [17]: patients can suffer from severe joint pain, swelling, stiffness, 
joint instability and weakness [17]. Various types of exercise are recommended for 
improving the function and symptoms of osteoarthritis, including aerobic, resistance activities 
and aquatic exercises [17]. For the majority of patients a combination of physical activity 
such as aerobic and local strengthening activities is optimal [17]. These benefits of physical 
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activity are maximised when associated with other lifestyle modifications that reduce body 
weight. 
1.3  The neuroendocrine control of appetite 
The studying of the effect of different types of exercise on appetite and energy intake was the 
subject of several publications over the last decade. These aim to investigate the basic 
mechanisms responsible for exercise-related changes in appetite and why certain types of 
exercise increases hunger and others reduce it – as will be discussed later in section 4 – which 
are not yet well understood [53-56]. Therefore it is important to understand the physiology of 
normal appetite control and its role in the regulation of body energy homeostasis, particularly 
during the performance of various acute and chronic physical activities.  
The last decade has witnessed great advances in understanding of the complex 
integration between peripheral and central neuroendocrine mechanisms that regulate food 
intake and energy expenditure through diverse hormonal, neuronal and metabolic signals [53, 
57, 58]. Peripheral hunger and satiety signals require central integration to achieve efficient 
energy homeostasis [59]. Hormones released from the gut (the largest endocrine organ in the 
body [60]) and the adipose tissue play a key role in the regulation of food intake and energy 
homeostasis [53, 57]. In addition to these peripheral hormonal signals, the afferent neuronal 
vagal signals constitute feedback mechanisms that ultimately regulate appetite and 
subsequently food intake centrally at higher brain centres, including the hypothalamus and 
brainstem [61, 62]. This gut-brain axis has been described as the communication line between 
the gastrointestinal tract and the central nervous system (CNS) in modulating food intake [57, 
58, 61]. 
In the next section, the various roles of the central nervous system on appetite 
regulation and energy homeostasis are discussed – particularly the hypothalamus and its 
important nuclei such as the arcuate nucleus that plays an important role in appetite 
regulation. In addition, the roles of the brainstem and the gastrointestinal vagal afferents are 
briefly reviewed. This is followed by discussion of five appetite-related gut hormones and 
their roles in appetite regulation. Towards the end of the section, the use of appetite 
regulating gut hormones in obesity treatment is discussed. 
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1.3.1 The role of the central nervous system in the 
regulation of appetite  
Appetite regulation is controlled by complex neuronal pathways that have reciprocal 
connections between the hypothalamus, brainstem and higher cortical areas [61]. These 
central nervous system sites interpret and integrate the various signals to provide coordinated 
feeding and energy expenditure responses to prevailing conditions [62]. In this regard, the 
hypothalamus and brainstem are the main central nervous system areas that regulate body 
energy homeostasis, as they receive peripheral neural and hormonal signals that relay 
information about nutritional state and adiposity [57]. Signals from the periphery – e.g., gut 
hormones – may influence food intake at three sites:  
• the vagus nerve,  
• brainstem and  
• hypothalamus [58].  
Signals from higher cortical centres are integrated with peripheral signals within 
hypothalamic nuclei [61]. Clearly, there is a complex neuronal network within the central 
nervous system that controls energy homeostasis [58]. 
1.3.1.1  The role of the hypothalamus 
The hypothalamus is located at the base of the brain, around the third ventricle [63]. It is an 
important region of the central nervous system that integrates signals from peripheral and 
central pathways, and plays a significant role in the regulation of a number of fundamental 
biological processes [63] – e.g., regulation of energy homeostasis [64] and appetite regulation 
[59]. Early experiments on the hypothalamus indicated that the lateral hypothalamic area is 
the “hunger centre” and that the ventromedial hypothalamic nucleus is the “satiety centre” 
[65]. However, later studies demonstrated that more nuclei and neuronal circuits are involved 
in the process of appetite control, and that these interact with brain stem and other higher 
cortical areas in the CNS [61]. In addition to this indirect access to the hypothalamus, there is 
an incomplete blood brain barrier at the median eminence of the hypothalamus and the area 
postrema of the brainstem, allowing direct access of peripheral circulating factors to the 
hypothalamus through fenestrated capillaries [57, 66, 67].  
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1.3.1.1.1 The arcuate nucleus  
The arcuate nucleus (ARC) of the hypothalamus is an important one, that acts as the site of 
integration of a number of neurological and blood-born signals [61] and therefore plays major 
roles in the regulation of food intake and energy homeostasis [57]. It integrates afferent 
inputs of different endocrine and neuronal signals – often derived from the periphery – and 
forwards these messages to other brain centres, which send the appropriate efferent response 
signals [53]. Also, the arcuate nucleus communicates with other nuclei in the hypothalamus, 
such as the lateral hypothalamic area and dorso-medial nucleus [61]. In the arcuate nucleus 
there are two major neuronal populations with opposing effects on food intake and weight 
gain: namely, the orexigenic or appetite-stimulating neurons, and the anorexigenic or appetite 
suppressing neurons [57, 63].  Both of these neuronal populations project into the adjacent 
paraventricular nucleus  [61]. The balance between activities of these neuronal circuits is 
critical to body weight regulation [59]. In this regard, there are many neuropeptides that 
influence short- or long-term changes in body weight and associated factors when they are 
administered centrally [41]. These include orexigenic signals such as galanin, melanin 
concentrating hormone, g-aminobutyric acid, hypocretins/orexins, and the anorexigenic 
oxytocins and the corticotropin-releasing hormone family of peptides as well as neurotensins 
[41]. However, the following will focus on major neurotransmitters whose expression is 
known to be altered by negative energy balance.  
1.3.1.1.1.1 The orexigenic neurons 
Orexigenic neurons are those containing neuropeptides that stimulate appetite [63] and are 
medially located in the arcuate nucleus of the hypothalamus. These neurons co-express 
neuropeptide Y (NPY) and Agouti-related protein (AgRP) [57, 68]. The two are commonly 
discussed in the literature.  
1.3.1.1.1.1.1 NPY and AgRP 
NPY, a 36-amino acid peptide expressed in the central and peripheral nervous systems, is one 
of the most powerful orexigenic agents known [69]. NPY and the other members of the NPY 
family exert their effects via at least five known Y receptors  – Y1, Y2, Y4, Y5 and Y6 [69].  
Of these five, NPY is thought to stimulate food intake through interactions with target 
neurons at the hypothalamic Y1 and Y5 receptors particularly [69].  A recent study on mice  
indicates that both are needed in mediating hyperphagic effects, hence dual deletion of Y1 
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and Y5 was needed to reduce food intake [69]. In contrast, AgRP increases food intake 
through antagonism of melanocortin (MC3) and (MC4) receptors [61, 70]. NPY and AgRP 
form a feedback loop with pro-opiomelanocortin (POMC) and cocaine and amphetamine-
related transcript (CART) neurons through the release of CART and of the neurotransmitter 
gamma-aminobutyric acid (GABA), and via interactions with MC3 and Y1 receptors 
expressed on POMC/CART neurons [70-72]. Also, NPY/AgRP neurons project extensively  
to other nuclei within the hypothalamus, including the paraventricular nucleus LHA and 
dorso-medial nucleus [61]. A single intra-cerebroventricular injection of NPY acutely 
stimulates feeding in rodents [70]; while injection of NPY antagonists centrally reduces their 
food intake, and chronic administration of NPY into the PVN induces sustained hyperphagia 
and weight gain [70].  
In addition to the central mechanisms that affect the function of NPY/AgRP neurons, 
these neurons are influenced by signals from peripherally-secreted, appetite-related hormones 
such as leptin, which is an adipose-derived satiety hormone, and insulin, which has similar 
effects on appetite. NPY/AgRP are also influenced by gut-derived, appetite-regulating 
hormones including the satiety hormones peptide tyrosine tyrosine (PYY) and glucagon-like 
peptide-1 (GLP-1); and the hunger-promoting hormone ghrelin [70]. Therefore, the 
NPY/AgRP secreting neurons are activated by ghrelin and inhibited by PYY and GLP-1 and  
the other appetite-related hormones that suppress food intake such as insulin and leptin [70].  
Leptin is secreted by white adipose tissue cells at concentrations proportional to fat mass, 
with a relatively long half-life. Leptin administered to rodents peripherally or centrally 
reduces food intake and body weight and increases energy expenditure [62]. In contrary, low 
circulating levels of appetite-suppressing hormones such as leptin, insulin and PYY3-36, 
and/or raised levels of ghrelin similar to those observed during fasting, lead to increase in 
NPY/AgRP neuronal activity and increased appetite [70].  
1.3.1.1.1.2  The anorexigenic neurons 
The arcuate nucleus of the hypothalamus also contains anorexigenic neurons that inhibit 
appetite and oppose the orexigeneic neurons [63]. These neurons express a-melanocyte 
stimulating hormone (a-MSH), derived from pro-opiomelanocortin, and cocaine and 
amphetamine-regulated transcript [57, 61, 73]. 
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1.3.1.1.1.2.1 alpha-melanocyte stimulating hormone (a-MSH) 
a-MSH is produced from POMC and binds to MC4 receptors to suppress food intake [74]. 
More than 70 different mutations of MC4 have been associated with obesity, and about 6% is 
found in cases of severe early-onset diabetes [75].  However, Cancell et al. 2012 debate the 
prevailing idea that the neighbouring neurons, namely the orexigenic appetite-stimulating 
AgRP/NPY, increase feeding by opposing the anorexigenic actions of POMC neurons; and 
instead state that only AgRP neuron activation – not POMC neuron inhibition – is sufficient 
to promote feeding [76]. 
1.3.1.2  Role of the brainstem and gastrointestinal vagal 
afferents 
Numerous studies indicate the pivotal roles of signals from the periphery in transmitting 
information via afferent vagal fibres to the caudal brainstem or directly to the hypothalamus 
[57, 58, 60, 62, 63, 70, 77, 78]. Within the brainstem, the dorsal vagal complex is crucial in 
relaying and interpreting these signals prior to reaching the hypothalamus [61]. The DVC 
consists of the dorsal motor nucleus of the vagus, the area postrema and the nucleus of the 
tractus solitarius [61]. Hormonal and neuronal signals from the gastrointestinal tract that 
relate to meals are received via the blood in the area postrema [58] and through vagal afferent 
fibres, and converge on the NTS of the brainstem [57]. In the NTS, the neuronal projections 
carry signals to the hypothalamus: these brainstem centres are reciprocally connected with 
hypothalamic nuclei controlling energy balance [61]. Evidence suggests that some appetite-
modulating hormones affect appetite through the vagus nerve [63, 78], as afferent neurons of 
the vagus nerve provide a pathway for gut peptides by triggering ascending pathways from 
the brainstem to the hypothalamus [77]. There are various mechanisms that operate at the 
level of vagal afferent neurons and may modulate the effect of gastrointestinal satiety signals 
[77]. This pathway offers a potential advantage in that hormones are able to have an influence 
at a site distant from the central nervous system [78] such as the gastrointestinal. This may 
explain why vagotomy – transaction of the vagus nerve – abolishes some of the centrally 
mediated effects of the peptide gut hormones on appetite regulation [63].  
1.3.2 Gut hormones and appetite regulation 
The gastrointestinal tract (GIT) is described as the largest endocrine organ in the body, as it 
releases more than 20 different regulatory bioactive peptide hormones [57, 61]. The concept 
of the gut as an endocrine organ is not new, as one of its hormones, cholecystokinin (CCK), 
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which has appetite inhibitory actions, was reported over 35 years ago [59]. Currently, the 
neuroendocrine role of the gut is one of the rapidly expanding fields of multidisciplinary 
scientific research [59]. Over the last two decades, the physiological influence of gut 
hormones on appetite regulation and energy homeostasis has been a dynamic area of research 
[57, 60, 78]. After a meal, nutrients pass into the gastrointestinal tract and this triggers the 
release of a number of gastrointestinal peptides and signals to optimise the digestive process 
[59]. Some of these gut peptides function as short-term satiety signals and possibly long-term 
regulators of body weight [59]. 
Gut hormones contribute to short-term changes in feelings of satiety and hunger [57, 
59, 62]. These peptides may reduce food intake by decreasing hypothalamic orexigenic 
appetite-stimulating signals and increasing anorectic appetite-suppressing signals [60]. 
Another effect of these peptides is to mediate inhibitory feedback on intestinal transit 
contributing to prolonged gastric distension and increased satiety between meals [79]. These 
combined central nervous system effects and ‘intestinal brake’ mechanisms [79] mediated by 
gut peptides facilitate the control of food intake and the transit of food through the GIT after 
meals [57]. The functions of appetite-regulating gut hormones vary: e.g., ghrelin is referred to 
as the appetite-stimulating hormone, or hunger hormone, whereas PYY, PP, GLP-1 and CCK 
act as satiety or appetite-suppressing hormones. Research indicates that gut hormones can be 
manipulated to regulate energy balance and that obese individuals retain sensitivity to the 
actions of gut hormones [59]. The positive effects achieved by bariatric surgery are partially 
related to its effects on modulating secretion of several gut-derived hormones including 
decreasing ghrelin secretion and increasing PYY or other satiety-inducing gut hormones [60]. 
1.3.2.1 Ghrelin  
Ghrelin is the only known appetite-stimulating gut-derived hormone, and is thus sometimes 
called “the hunger hormone” [60]. Ghrelin was first discovered as an endogenous ligand for 
the growth hormone secretagogue receptor; and is released into the circulation from the 
stomach [80, 81]. It is produced and released mainly by the gastric oxyntic cells, with the 
remaining circulating ghrelin being released by parts of the small intestine (duodenum and 
ileum) and the large intestine (caecum and colon) [62]. Ghrelin is composed of 28 amino 
acids and is modified by the addition of an octanoyl group to the serine residue at position 
three [81]. This acylation is necessary for ghrelin to bind to the GHS-R and to cross the blood 
brain barrier [81].  
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Ghrelin stimulates appetite and increases food intake, with circulating levels rising 
during fasting and falling after nutrient ingestion, in both rodents and humans [60]. In rats, 
central or peripheral administration of acylated ghrelin stimulates food intake and growth 
hormone release acutely, while chronic administration causes weight gain [82]. In humans, 
intravenous infusion or subcutaneous injection of ghrelin increases feeling of hunger and 
food intake [64, 83, 84]. Ghrelin release is not related to gastric distension, but to food 
ingestion, as it is observed that its release is not inhibited following water ingestion [82]. 
Circulating ghrelin concentrations exhibit a diurnal rhythm that gradually rises 
throughout the day, reaching a zenith between 0100 and 0200 h [83]. Ghrelin levels also 
change in response to fasting and meals; rising 1–2 h before the initiation of a meal and 
falling to trough levels 1–2 h after a meal [83]. Considerable evidence in the literature 
implicates the involvement of ghrelin in short-term energy homeostasis through its effects on 
mealtime hunger [83, 84]. Data also suggest that ghrelin plays a role in meal initiation [60, 
83]. High plasma concentrations of ghrelin occur amongst individuals initiating meals 
voluntarily without time- or food-related cues, and also before every meal, in subjects who 
follow fixed feeding schedules [84]. It is also reported that ghrelin injections stimulate food 
intake rapidly and transiently by increasing the number of meals and meal initiations [84]. 
Wren et al. (2001) indicate that ghrelin infusion at physiological concentrations stimulate 
food intake by 28% at a subsequent free-choice meal and increase overall food intake over a 
24-hour period compared with saline infusion [85]. Spontaneous changes in endogenous 
circulating ghrelin levels are probably triggered by sympathetic nervous output [83, 86]. In 
addition to these short-term effects of ghrelin on energy homeostasis and its probable role in 
meal initiation [83], ghrelin is involved in long-term weight regulation, as it fulfills the 
criteria for an adiposity-regulating hormone [54, 83, 84]. For example, circulating ghrelin 
levels are elevated in individuals with anorexia nervosa [86], but fall after weight regain [54, 
86]. In contrast, low levels of plasma ghrelin rise after weight loss in obese subjects, which 
indicates an inverse correlation with adiposity [54, 59, 87, 88]. [59, 87, 89]. Circulating levels 
of ghrelin are also negatively correlated with body fat, fat mass [54, 59] and BMI [84], as 
well as circulating concentrations of leptin [86, 89] and insulin [54]. In obese subjects, 
plasma ghrelin decreases in direct proportion to the degree of insulin resistance [89].  
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1.3.2.2 Peptide tyrosine tyrosine (PYY) 
PYY is a 36-amino acid appetite-suppressing gut peptide hormone [64]. Like similar 
peptides, NPY and Pancreatic Polypeptide (PP), PYY belongs to the ‘PP-fold’ family of 
peptides [57]. These are all 36 amino acids in length and share a common tertiary structural 
shape known as the PP-fold [57, 64]. Members of the PP-fold family mediate their effects via 
Y-receptors [90], a family of receptors comprising different receptor subtypes (Y1, Y2, Y4, 
Y5 and Y6). PP-fold peptides exhibit varying affinities for Y receptor subtypes [63].  
PYY was first isolated in 1980 from porcine lower intestinal mucosa [91] and so 
named due to the presence of a tyrosine residue (amino acid abbreviation, Y) at both ends of 
the 36-amino acid polypeptide [92]. The L cells of the gastrointestinal tract are the major 
source of PYY, with the highest levels found in the rectum [59, 64]. PYY is present in two 
endogenous forms: PYY1-36 and PYY3-36. The latter is the major circulating form that crosses 
the blood brain barrier freely [90].  PYY3–36 is also more potent in suppressing hunger than 
PYY1-36 [93].  
In contrast with ghrelin, PYY circulating concentrations are lowest during fasting 
[71]. PYY plasma concentrations start to elevate 15 minutes after a meal, reaching a peak at 
one to two hours after food intake and remaining high for several hours [92]. Secretion of 
PYY is most likely via the vagus nerve, through a neural reflex, as its secretion from the 
lower GIT occurs before foods reaches the distal gut [94, 95]. PYY3–36 inhibits food intake by 
acting through Y2 receptor in the arcuate nucleus [94]. Circulating levels of PYY3-36  are 
influenced by many factors; and these include caloric intake and meal composition [60], with 
higher levels being seen following fatty meals compared with meals containing high protein 
or carbohydrate levels [94]. Furthermore, plasma levels of PYY increase in malabsorption 
states [94] as well as following bariatric surgical procedures, and this may contribute to the 
decrease in appetite and food intake after such surgery [96]. In contrast, circulating PYY 
levels are suppressed in patients with morbid obesity [94]. In humans, PYY levels correlate 
negatively with BMI and waist circumference, and postprandial PYY levels may predict the 
pattern of long-term weight changes [92]. Compared with a saline infusion, the infusion of 
PYY leads to an approximately 30% reduction in food intake in humans at a subsequent meal 
[97]. All of these findings indicate that PYY plays a significant role in reducing food intake 
in humans [59]. 
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1.3.2.3  Pancreatic polypeptide (PP) 
Similar to the PYY, PP is another 36-amino acid anorexigenic peptide gut hormone from the 
‘PP-fold’ family of peptides [57, 94]. However, it is released from PP cells – sometimes 
called F cells – in the endocrine pancreatic islets of Langerhans [61]. PP has great affinity for 
the Y4 receptor in the brainstem and hypothalamus [61]. It is thought that PP’s central actions 
may be mediated via the Y4 receptor in the area postrema of the brainstem, an area with a 
‘leaky’ blood brain barrier [94]. It is also thought that PP exerts its satiety actions via several 
central and peripheral mechanisms that include delayed gastric emptying [94]. This 
observation may explain the different effects of PP on appetite and food intake according to 
the route of administration. Indeed, a satiety effect of PP is observed after peripheral 
administration, whereas food intake is stimulated after central administration of PP [61]. 
The role of PP in appetite regulation has been investigated for over 30 years [59]. 
Circulating PP level rises after a meal in proportion with the caloric content of that meal – PP 
level remains elevated for up to six hours after food intake [61, 94]. In mice, acute PP 
administration via a peripheral route leads to a prolonged decrease in food intake as it delays 
gastric emptying [94]; and chronic administration of PP reduces body weight of obese mice 
[98]. It is also noticed that transgenic mice over-expressing PP are lean [99]. In humans, an 
intravenous infusion of PP has been shown to result in a 25% reduction in 24-hour food 
intake in healthy lean subjects [100]. Similarly to PYY3-36, lower PP levels are reported in 
obese compared with lean subjects [94], although some studies report similar levels in both 
obese and lean [94]. Some researchers link the satiety effects of PP to the secondary effect of 
delayed gastric emptying that occurs after intravenous administration of PP [94]. In view of 
this conflicting data, researchers recommend long-term studies to define the full potential of 
PP as an anti-obesity target [95]. 
1.3.2.4 Glucagon-like peptide-1 (GLP-1) 
GLP-1, GLP-2, oxyntomodulin (OXM) and glucagon are proglucagon-derived satiety 
hormones [61].  Proglucagon is expressed in the pancreas, L-cells of the small intestine and 
in the NTS of the brainstem [101]. Glucagon is produced in the pancreas, whereas GLP-1, 
GLP-2 and OXM are produced in the intestine, mainly by the L-cells of the GIT, the same 
endocrine cell type that releases PYY [63, 64]. GLP-1 is a potent incretin gut hormone i.e. a 
hormone that stimulates insulin secretion and is secreted from enteroendocrine cells into the 
blood stream within minutes of eating [102]. One of the main physiological roles of GLP-1 is 
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to regulate the amount of insulin that is secreted after eating [102]. Insulin secretion is 
released post-prandially in proportion to energy ingested [63, 64, 102]. Secretion of GLP-1 is 
mediated by vagal stimulation, acetylcholine and gastric inhibitory polypeptide (GIP) [103]. 
Circulating GLP-1 levels rise after a meal and fall in the fasted state [61]. However, GLP-1 is 
rapidly inactivated in the circulation, resulting in a short half-life of 1-2 minutes [61]. 
In rodents, food intake is inhibited when GLP-1 is injected into the CNS [64]. 
Similarly, peripheral administration of GLP-1 also inhibits food intake in animals [104]. 
Similar findings are reported in humans, as GLP-1 reduces food intake, and also suppresses 
glucagon secretion and delays gastric emptying [61, 104]. These effects of intravenous 
administration of GLP-1 in normal and obese humans occur in a dose dependent manner 
[105]. The satiety effect of GLP-1 is attributed to a delayed gastric emptying rate [70], and is 
thought to be mediated through vagal and brainstem pathways [57].  
1.3.2.5 Cholecystokinin (CCK) 
CCK is the prototypical satiety gut hormone as it was the first gut hormone for which effects 
on appetite were systematically researched [63]. It still remains one of the most intensively 
studied appetite regulating hormones [59]. Derived from a 115-amino-acid precursor, CCK is 
secreted from I cells of the small intestine, mainly in the duodenum and jejunum [59] in 
response to nutrients in the gut, particularly fat and protein-rich meals [59]. Circulating CCK 
levels rise approximately 5-fold in response to a meal [59, 106]. Two G-protein-coupled 
receptors for CCK (the CCK-1 and CCK-2 receptors, previously known as the CCK-A and 
CCK-B receptor, respectively) have been identified [63]. The effects of CCK on gallbladder 
contractility, gut motility and GI secretion are mediated predominantly by the CCK-1 
receptor [107]. CCK-1 receptors are distributed peripherally in the gastrointestinal tract, on 
vagal afferent nerve fibres, and in areas within the CNS that are involved in the regulation of 
food intake [57], whereas CCK-2 is found in the cortex, hypothalamus, vagal afferents and 
gastric mucosa [57]. 
The mechanisms by which CCK alter appetite are debatable [63]. The inhibitory 
effect of CCK on food intake is thought to be mainly related to its effects on gastric emptying 
and GIT motility [108]. High doses of CCK, in common with many gut peptides, also induce 
nausea [63]. However, a satiety effect of CCK is seen at circulating levels below those that 
cause nausea [63]. CCK alone has a very short term effect on appetite and has a 1-2 minutes 
half-life [59, 109]. Furthermore, chronic administration of CCK alone does not result in 
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weight loss [59]. All of the available data demonstrates that the actions of CCK on food 
intake are short-lived [63, 109], as its anorectic effect disappears after 24 hours of infusing 
CCK continuously [110]. There are also concerns about the role of CCK in the development 
of pancreatitis and pancreatic carcinoma [63]. All of these findings cast doubts on the future 
use of CCK as a potential novel obesity therapy [59] and make it unlikely that manipulating 
CCK signalling mechanisms will prove a promising therapeutic strategy for obesity [63]. 
1.3.3 The potential use of appetite regulating hormones in 
the treatment of obesity  
The search for an anti-obesity drug that produces sustained weight loss with minimal side 
effects is rife with difficulties, in part because of the significant built-in redundancy in the 
mechanisms that control energy balance and food intake [95, 111-113]. These mechanisms 
are influenced by other physiological mechanisms, as well as social and psychological factors 
that limit the effectiveness of all past and currently available anti-obesity drugs [112]. Anti-
obesity drugs aim to increase metabolic rate, reduce the absorption of nutrients, or increase 
satiety [111]. Drugs used in the pharmacological therapy of obesity include thyroid hormone, 
dinitrophenol, amphetamines and their analogues, e.g. fenfluramin [111]. At present, only 
orlistat, a pancreatic lipase inhibitor is available for the long term treatment (≥ 24 weeks) of 
obesity in some countries such as the United Kingdom and the United States [111], as 
sibutramine [114] and rimonabant [115] were withdrawn from the international market due to 
adverse cardiovascular and psychiatric events, respectively [111, 114, 115].  
Recent research on the appetite-stimulating hormone ghrelin, as well as appetite-
suppressing hormones such as PYY and GLP-1, have opened up new possibilities [57, 112] 
based on recent evidence that these hormones can influence appetite in several animal and 
human studies [63, 94, 97, 116]. Growing evidence is accumulating regarding the potential of 
gut hormones or their pathways of action in the treatment of obesity, as they may offer an 
alternative to centrally acting drugs [57, 59]. For example, PYY may play an important role 
in reducing food intake, although its mechanism of action remains to be fully elucidated [95], 
and there are reports of nausea as a side effect when given in high doses to humans [59]. 
However, researchers are still interested in exploring its potential use as an anti-obesity drug 
in both lean and obese individuals, with novel drugs designed to mimic the action of PYY 
itself, or targeted against the Y2 receptor [94]. Also, numerous studies suggest that longer-
acting GLP-1 mimetic peptides such as Exedin-4 (which is isolated from the venom of a 
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lizard native to southwestern American states), and its synthetic version, Exenatide, are 
approved for the treatment of type 2 diabetes mellitus due to their incretin properties [57, 
102]. Recent data suggest additional use of a human GLP-1 analogue, Liraglutide, as a 
promising anti-obesity drug, albeit currently with a 50% chance of nausea and vomiting 
[116]. Therefore, gut peptides may only have modest benefits as an obesity treatment, a 
major limitation appearing to be numerous side effects, as well as the limited weight lowering 
effects that last only as long as the drug is being taken, as well as weight regain after 
discontinuation [113].   
To overcome some of the limitations of gut hormones as a therapy for obesity 
mentioned above, researchers and pharmaceutical companies are investigating dual 
administration. The concept of administering more than one gut hormone or gut hormone 
mimetic in order to produce a better additive effect on food intake inhibition was based at 
least partly on the fact that appetite regulating gut-hormones are co-released [57]. Examples 
of those combinations are PYY and GLP-1 [117], and PYY and OXM [118]. Evidence 
suggests that such combinations are more effective than individual administration [112]. In 
future, the poly-therapeutic strategy will hopefully rival surgery in terms of efficacy, safety 
and maintaining weight loss [112]. However, time will tell if promising pre-clinical data 
translates into clinical benefit [57]. Currently, liraglutide, a GLP-1 analogue currently 
marketed for the management of diabetes, is the most promising new anti-obesity drug 
nearing market launch [111]. However, it is uncertain if it will meet the strict regulations 
needed for licensing as a new anti-obesity drug in people who do not have diabetes [112]. 
Based on emerging understanding of the physiological role of gut hormones in the 
regulation of energy homeostasis and food intake, researchers are currently interested in 
exploring the effects of exercise, which is one of the best approaches for both prevention and 
treatment of obesity, on the circulating concentrations of gut hormones, both in the short and 
long term. Such an understanding may help in defining the role of exercise in combination 
with future strategies for weight management in overweight and obese subjects. 
1.4  The effects of exercise on appetite and appetite 
regulating gut hormones 
In recent years, researchers have become more interested in exploring the various effects of 
physical activity on body weight through better understanding of the impact of structured 
exercise programs on different aspects of appetite, as a step to defining their role in the 
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management of obesity. In this regard, investigation of the effects of acute and chronic 
structured exercise interventions on the motivation to eat, food intake, appetite regulation and 
appetite-regulating gut hormones is an area that has received great consideration over the last 
decade [119-121]. The recent understanding of the metabolism and effects of various 
appetite-regulating gut-derived hormones such as ghrelin, PYY and PP, in addition to other 
appetite regulating hormones such as leptin and insulin, has enhanced the interest in using 
these hormones as additional measures for the assessment of the effects of exercise on 
appetite and appetite control [119, 122, 123]. Therefore, several studies have recently 
correlated alterations in appetite with changes in plasma levels of the appetite-regulating gut-
derived hormones following either acute [124-129] or chronic exercise [130-132]. However, 
it is still controversial as to whether acute or chronic exercise increases, decreases or has no 
effect on appetite, and whether these changes are affected by other factors such as age [119, 
123, 132], sex [122, 133], and body mass index [124, 133]. The effects of exercise on 
appetite control were also correlated with the various type of exercise (aerobic versus 
resistance training) [124, 125, 128, 130, 131], as well as the duration [133], frequency [119, 
120, 122], intensity [93],  timing of the exercise relative to food intake (fasted or in the 
postprandial state) [134, 135], and ingestive behaviour before and after exercise [136]. 
In this section, the effects of exercise on appetite and appetite-regulating gut 
hormones will be discussed at length. This will help in better understanding the role of 
exercise in long-term weight maintenance, and, potentially, how the effects of exercise could 
be enhanced.  
1.4.1 Exercise and appetite  
Beneficial effects of exercise on appetite regulation have been suggested in the literature, but 
the exact mechanisms are not yet well understood [120, 121]. At the physiological level, the 
regulation of appetite is under neuroendocrine control involving both centrally and 
peripherally mediated signals and has already been discussed (section 1.4.). In this regard, 
growing interest has developed in studying the effects of various types of exercise on the 
circulating concentrations of appetite-regulating gut hormones such as the orexigenic 
hormone ghrelin, anorexigenic hormones such as PYY, PP, and GLP-1, in addition to other 
anorexigenic hormones such as leptin and insulin [120, 122].  
Understanding the exact mechanisms of eating behaviors in general and appetite in 
particular are highly complex as they involve strong external influences that affect food 
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intake in free-living humans that can easily overcome normal physiology [120], such as 
environmental, psychological, social and cultural stimuli [137].  This interaction between 
external stimuli and internal stimuli may explain the conflicting results on the effects of 
exercise on appetite and related-hormones. Moreover, the need for reliable objective tests that 
assist in measuring the effects of exercise on appetite is essential for better understanding of 
the complexity of appetite regulation. 
1.4.1.1 Appetite assessment methods in appetite research 
Appetite is defined as the internal driving force for the search, selection and ingestion of food 
[138]. Appetite is usually linked to hunger, which is typically defined as the need or desire 
for food [138]. In appetite research, various methods have been used to assess alterations in 
appetite including visual analogue scales (VAS) [128, 139], food intake [119, 140], and more 
recently the circulating concentrations of various appetite-regulating hormones [129, 130], 
either in the fed and / or fasted state. In various studies, researchers used all or some of these 
methods to assess the effects of exercise on appetite. The reliability and objectivity of the 
various methods vary [138, 140-143]. For example, visual analoug scales are subjective 
scales that rate appetite changes indirectly [139]. Visual analogue scales consists of questions 
and answers about appetite such as ‘How hungry are you?’, ‘Not at all hungry’ vs. ‘As 
hungry as I have ever felt’ [119, 139]. When used appropriately, subjective appetite ratings 
have been shown to have good reproducibility and are considered reliable for appetite 
research [139]. Appetite level was recently assessed using the Electronic Appetite Ratings 
System (EARS), which is a validated electronic version of the visual analogue scale [144]. 
Another method used for assessing the influence of exercise on appetite is the 
measurement of food intake. In this regard, the ad libitum buffet meal is widely used for 
research purposes [61, 142]. In this method a selection of everyday palatable foods are 
offered to participants during the study. Participants are allowed to select freely and eat the 
foods and amounts they would like [142]. Despite inherent limitations of the ad libitum buffet 
meal, research indicates that it is a reproducible method that can be used to assess differences 
in energy intake driven by differences in appetite [141]. However, large variations in two 
separate occasions may occur in some subjects despite similar feeding conditions, and this 
phenomenon may be minimised by standardisation of the dietary intake prior to the 
assessment [141]. Another limitation of using food intake as an indicator of alterations in 
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appetite is that changes in appetite do not necessarily lead to changes in food intake in all 
individuals [141, 142]. 
An additional measure that has been used by several researchers in appetite research 
recently is the measurement of plasma levels of appetite-regulating gut-derived hormones, 
particularly ghrelin, the “hunger hormone” [122], the satiety hormone PYY [123], in addition 
to other satiety hormones such as leptin [120, 145]. These appetite related hormones have 
been in addition to other methods of appetite assessment as mentioned above [128, 131], or 
sometimes alone to assess possible alterations in appetite regulation [125, 126, 130]. Several 
studies recently demonstrated that moderate to intense exercise may influence some or all of 
the appetite-regulating gut-derived hormones [93, 119, 128, 130]. In the following section, 
nine identified studies that investigated the effects of acute and chronic exercise on appetite 
and appetite regulating gut hormones in adults and adolescents will be discussed. These 
studies are listed in Table 1.1. 
1.4.2 The effects of acute exercise on appetite and 
appetite regulating gut hormones 
Numerous studies have measured appetite-regulating gut hormones to investigate the effects 
of acute exercise on appetite [124-126, 128, 129, 133]. However, these studies were 
inconsistent as they had different aims, enrolled diverse populations, and used different 
protocols to investigate different types, forms and intensities of exercise. All of these 
variables make interpretation difficult and sometimes contradictive. For example, a cross-
over randomised control study was conducted by King et al. [126] on a group of 9 lean 
healthy males (mean BMI 23.6 ± 0.4) to assess the effects of one bout of 90 minutes of 
running at 68.8 ± 0.8 of maximum oxygen uptake on appetite and energy intake. Appetite 
was assessed using visual analogue scale and measurements of one of the peptide gut 
hormones, namely the appetite-stimulating hormone, acylated ghrelin. Energy intake was 
assessed by an ad libitum buffet meal. Results of the study clearly indicated that exercise 
transiently suppressed appetite and circulating acylated ghrelin hormone levels for a few 
hours after exercise compared to the control group [126]. A similar finding of suppression of 
appetite and the circulating levels of ghrelin, as well as a corresponding elevation in levels of 
the satiety hormone PYY, was observed by Broom et al. (2012) [128] during and after acute 
exercise in a cross-over randomised control study on 11 healthy normal weight young male 
students who undertook three 8-hours trials of either resistance training that involved a 90-
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minute free weight lifting session followed by a 6.5 h rest period, or aerobic exercise of a 60-
minute run followed by a 7 h rest period; or a control group who rested for 8 hours. This 
observation was noticed after both aerobic and resistance training [128], and the researchers 
indicated significant interaction effects for hunger, ghrelin and PPY that lead to suppressed 
hunger in both of the interventions groups. However, in that study the appetite-suppressing 
hormone PYY increased only during aerobic exercise [128]. As noted above, these studies 
[126, 128] enrolled only lean young males, and these are possible limitations as later studies 
referred to the importance of obesity and increased BMI as important factors in hormonal 
response. 
In this regard, Thomas et al. (2012) investigated the impact of body weight on the 
hormonal response to exercise [124]. In their study, they examined the effects of an acute 
high-volume whole-body resistance exercise program on plasma levels of the appetite-
stimulating hormone ghrelin in sedentary obese (n=10) and lean young men (n=9). The obese 
group included 5 class 1 obese (BMI = 30.00-34.99 kg/m2), 5 class 2 / class 3 obese (BMI = 
35-39.99 kg/m2) / (BMI ≥ 40), in addition to 9 lean men (BMI < 25 kg/m2). All participants 
completed an acute resistance exercise testing protocol (6 exercises, 3 sets of 10 repetitions at 
85%-95% of 10-repetition maximum weight, with 120- and 90-second rest periods). Blood 
samples were collected pre-, mid-, and immediately post-exercise and during recovery. In this 
study, ghrelin levels increased in class 2/3 and lean groups but not in class 1 group; however 
only people in the class 2/3 obese group exhibited significantly greater ghrelin levels than 
those in the class 1 obese and lean groups [124]. There are a few limitations of this study as 
addressed by the authors, such as reporting total ghrelin levels instead of acylated ghrelin, 
making comparison with similar studies difficult. Additionally, and similar to other studies, 
only young men were included. 
Unlike previous studies, the randomised crossover study of Martins et al. (2007) [129] 
enrolled both sexes (6 lean young males and 6 lean young females), aiming to investigate the 
acute effects of exercise on the postprandial levels of appetite-related hormones (namely: 
ghrelin; PYY, GLP-1, PP), energy intake and subjective measures of appetite. Participants 
had a standardised breakfast that was followed an hour later by either 60 minutes of cycling 
at 65% of maximal heart rate, or rest. Their appetite was assessed using visual analogue scale 
and subsequent energy intake at a buffet meal was measured. The study showed that exercise 
significantly increased mean levels of the appetite-suppressing hormones PYY, GLP-1 and 
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PP, and that this effect was sustained at three hours after exercise completion only for GLP-1 
and PP but not PYY. However, postprandial levels of the appetite-stimulating hormone 
ghrelin were not significantly affected by the acute exercise. Hunger scores were significantly 
decreased during the exercise period, but this effect disappeared in the post-exercise period. 
This study therefore showed that hunger sensations were temporarily reduced in response to 
acute exercise of moderate intensity, and that this effect was not explained by the changes in 
the postprandial levels of ghrelin. Therefore, the researchers attributed the observed 'acute 
exercise-induced anorexia’ to the increased levels of GLP-1, PP and probably also PYY, 
albeit the latter was obviously transiently elevated by exercise [129]. These positive effects of 
acute exercise on appetite suppression may explain the utility of exercise for weight loss and 
weight regain prevention on the long-term. 
The above-mentioned study did not refer to any sex differences amongst participants. 
However, sex differences were reported in another study, with an indication of a lesser 
exercise-induced anorexia in women than in men [127]. That study investigated the appetite 
and hormonal responses to short-term exercise training programs in a group of 18 overweight 
and obese subjects (9 men and 9 women). Participants completed four bouts of exercise in 
conjunction with increased food intake to maintain energy balance, and four bouts of exercise 
without additional food intake, to induce an energy deficit [127]. The study found that in 
men, the area under the curve for acylated ghrelin levels was not different between 
conditions. Also, leptin concentrations were not different across conditions in either sex. 
However, in men but not in women, appetite was suppressed after exercise in energy balance 
compared to exercise during energy deficit. The study therefore demonstrated a clear sex 
difference in the effects of acute exercise on appetite and appetite-related hormones. The data 
indicate that women are less likely to lose body fat in response to exercise compared to men 
[127]. Therefore, the authors suggested that women may need to both decrease energy intake 
and increase energy expenditure in order to lose body fat [127]. These potential sex 
differences in hormonal responses to exercise have potentially important implications for 
exercise and dietary guidelines and should therefore be explored further. 
Some research has investigated the effects of different modalities of acute exercise on 
appetite and appetite regulating hormones. A recent randomized controlled trial studied ten 
active men who completed 3 trials: 45-min of resistance exercise (free and machine weights), 
aerobic exercise (running), or resting control (CON) [125]. The aim of this study was to 
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investigate the acute effects of these two types of exercise on appetite-regulating hormones 
and subsequent energy intake [125]. Circulating ghrelin concentrations were lower following 
resistance exercise compared with both aerobic exercise and CON. In contrast, fasting 
circulating PP concentrations were significantly higher after both aerobic exercise and 
resistance exercise compared with CON. These results indicate that aerobic exercise may be 
preferable for achieving short-term negative energy balance than resistance training [125]. 
The researchers also indicated that the acute responses and alterations observed in their study 
may provide a solid basis for future studies on the long-term effects of regular aerobic and 
resistance training on appetite and appetite regulating hormones.  
The aims and protocols of the above-mentioned studies are different, so it is difficult 
to draw solid recommendations out of them. However, three [126, 128, 129] of the six studies 
reviewed above reported decreases in the feeling of hunger after acute exercise, whereas the 
remaining three studies [124, 125, 133] did not find a significant difference in the feeling of 
hunger. With regards to the type of acute exercise, studies indicated that high intensity 
aerobic exercise such as running or cycling is followed by hunger suppression that lasts for 
few hours following cessation of exercise [127, 129]. In contrast, an appetite-suppressive 
effect was not reported after acute progressive resistance training in two studies despite the 
observed low plasma concentration of ghrelin hormone in these two studies [127, 129]. 
However, one study does report appetite suppression after acute progressive resistance 
training, and that study was limited to lean young males only [127].  
1.4.3 The effects of chronic exercise on appetite and 
appetite regulating gut hormones 
Interest in exploring the long-term effects of regular or chronic exercise on perceived hunger 
was observed recently [43, 130-134, 146]. However, only very few studies used the 
circulating levels of appetite-related hormones as an additional measure to assess the effects 
of regular exercise on appetite [130-132], in addition to the already known indicators such as 
ingestive behavior and food intake that were used in earlier studies [43, 133, 134, 146] (Table 
1.1.).  
In 2009, Jones et al. published an uncontrolled study on the effect of long-term 
aerobic training on plasma levels of five appetite-related hormones in overweight or obese 
adolescents [132]. After 32 weeks of exercise, there were decreases in both blood triglyceride 
levels and percent body fat. In addition, there was an increase in the plasma concentrations of 
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total PYY. This was considered a favourable outcome as PYY is a hormone that suppresses 
appetite and food intake [59]. In contrast, circulating levels of the appetite-stimulating 
hormone, ghrelin, were not affected by this type of long-term exercise training [132]. This 
study was limited to a specific age group (adolescents) and did not compare aerobic exercise 
with other modes of exercise, such as progressive resistance training. 
In contradiction, a longitudinal study in adults produced somewhat different results 
[131]. This study involved a group of 22 sedentary, overweight or obese men and women 
(age 36.9 ± 8.3 years; BMI 31.3 ± 3.3 kg/m2) [131]. Participants took part in a 12-week 
supervised aerobic (walking or running) exercise program (five times per week, 75% 
maximal heart rate). Researchers found differences between results determined in the fasting 
state or after meal ingestion. Exercise resulted in an increase in fasting plasma levels of 
acylated ghrelin as well as increased fasting hunger sensations. However, in the post-prandial 
state, there was an increase in the meal-induced rise in plasma GLP-1 levels (90-180 min), as 
well as a significantly greater suppression of acylated ghrelin levels. These changes would be 
expected to contribute to a greater feeling of fullness after exercise due to the increase in 
GLP-1 levels and the decrease in levels of the hunger hormone, ghrelin, later in the day. The 
authors therefore stated that the observed exercise-induced weight loss in the studied sample 
was not affected by the observed increased drive to eat in the fasting state, but seems to be 
related to the improved satiety response to a meal after chronic exercise [131]. Again, a few 
limitations were noted in this study, such as the small sample size as only 15 subjects 
completed the study and the investigation of one type of regular exercise, namely aerobic 
exercise. 
There is some evidence that aerobic exercise has differential effects on appetite 
regulation compared to progressive resistance training. In a more recent longitudinal 
controlled study that enrolled 33 inactive overweight and obese middle aged men (BMI 30.8 
± 4.2 kg/m2, age 49 ± 7 years), Guelfi et al. (2013) [130] investigated the effects of 12-weeks 
of aerobic exercise compared with resistance training on hunger and fullness, together with 
appetite-related hormones in both the fasted state and postprandially. People randomised to 
the aerobic exercise and resistance training arms completed 12-weeks of training, while those 
in a control group continued their usual daily routine. Both aerobic exercise and resistance 
training elicited a decrease in fat mass, while CON did not. However, no differences in 
hunger, either in the fasted state or in response to the energy intake, were observed in any 
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groups. In contrast, both fasting and postprandial feelings of fullness were higher following 
aerobic exercise, but not with resistance training or CON. No changes in plasma 
concentrations of ghrelin, PYY or PP were observed. The researchers therefore concluded 
that only aerobic exercise training but not resistance training is associated with an increase in 
satiety, and that these appetite changes were not accompanied by any observed alterations in 
the measured appetite-regulating hormones. The strength of this study is that it appears 
unique and well designed in comparing the effects of chronic aerobic and resistance exercise, 
in addition to the measurement of appetite regulating gut hormones [130]. However, the 
study had limitations such as recruitment of only men and using a liquid glucose drink rather 
than a mixed solid meal [130].  
Two reviews on the effects of exercise on appetite were found upon searching the 
literature in this field [120, 122]. The mini-review by Kaemer and Castracne (2007) was not 
comprehensive and was limited only to investigation of effects of exercise on circulating 
ghrelin and adiponectin levels [122]. In contrast, the review by Martins et al. (2008) was 
more comprehensive as it reviewed ten studies conducted between 1980-2008 on the effects 
of acute exercise (7 studies) and chronic exercise (3 studies) on appetite regulation and 
appetite hormones [120]. Overall, the authors reinforce the critical role of exercise in body 
weight management and indicated the need for more long-term studies to establish the role of 
chronic exercise on appetite control in obese individuals [120]. They also indicated other 
limitations in the reviewed studies with regards to the methods used in subjective and 
objective measures of appetite [120].     
The current review includes nine recent studies [124-126, 128-133] published on the 
effects of exercise on appetite and appetite regulating hormones since the above-mentioned 
reviews were published in 2007 and 2008. As discussed above, only three studies 
investigated the effects of chronic exercise on appetite and appetite-regulating hormones 
[130-132], compared to six studies on acute exercise [124-126, 128, 129, 133]. Only one of 
the three studies on chronic exercise was controlled and compared aerobic versus progressive 
resistance training [130]. However, that study was limited to men. It did report a positive 
effect of aerobic exercise but not progressive resistance training on the feeling of fullness, 
and this effect was not accompanied by relative alterations in the plasma levels of appetite-
regulating hormones, namely ghrelin, PYY or PP. This paucity of data, and the conflicts of 
  44 
existing data, indicate the need for future well-designed studies in this emerging area of 
research.  
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Table 1-1: Summaries of the studies published on the effects of acute and chronic exercise on appetite and appetite-regulating gut hormones 
Reference  Study design Participants Type  Exercise protocol  Appetite Gut Hormones Notes 
King et al., 
2010, [126] 
Cross-over 
randomised 
control 
9 M; young (22.2 
±0.8yr); leans BMI  
(23.6±0.4)  
Acute 
 
Only AE, running  for 90 
ms, VO2=70%, Blood  is 
taken 10 h after  Ex., used 
VAS 
↓ Hunger; 
After Ex. 
  ↓ Ghrelin, 
After Ex. 
Positive effects, but 
limited to young lean 
males and  did not 
compare AE vs .RT 
Broom et al., 
2009, [128]  
Cross-over 
randomised 
control 
11 M; young (21.1 ± 
0.3yr);  leans BMI (23.1 
±0.4) 
Acute 
 
3 groups: AE (running), RT 
(weight lifting) , C; VO2= 
68.8±0.8, used VAS and 
energy intake 
↓ Hunger; 
During Ex. 
↔ after meal 
↓ Ghrelin (AE 
&RT) 
↑ PYY (AE) 
↔ PYY (RT) 
Positive effects in AE, 
but limited to young 
lean males  
Thomas et al., 
2012, [124] 
Cross-over 
randomised 
control 
19M; young; lean 
group(n=9), obese 
C1(n=5), obese C2/3 
(n=5) 
Acute High volume, whole body 
RT; blood samples collected 
pre- mid- and postprandial  
N/A ↔ Ghrelin ( in 
leans & C1), but 
↑ Ghrelin (in 
C2/3) 
Ghrelin response to RT 
differs according to 
BMI; limited to young 
males 
Martins et al., 
2007, [129] 
Cross-over 
randomised 
control 
12 (6M+6F); young 
(25.9 ±4.6yr); leans BMI  
(22.0±3.2);  
Acute Subjects either cycled for 60 
mins at 65% of their mxHR 
or rested 1 hour, used VAS 
and energy intake 
↓ Hunger; 
During Ex. 
 
↔ Ghrelin 
↑ PYY, GLP-1, 
PP (During and 
after Ex.) 
The 'exercise-induced 
anorexia' after Ac.ex. is 
linked to ↑ PYY, GLP-
1, PP, not ghrelin 
Hagobian et 
al., 
2008, [133] 
Cross-over 
randomised 
control 
18 (9M+9F); young 
(M26.8 ±8yr), (F23.3 
±8yr); overweight/obese 
BMI  (M25.7 ±2.3), 
(F28.0 ±3.5)  
Acute Four bouts of Ex. (treadmill 
at 50-65%Po2) with energy 
added to the baseline diet 
and four bouts without; 
appetite questionnaire used  
↔ Hunger 
(F) 
↓ Hunger 
(M) 
↑ Ghrelin (F) 
↔ Leptin 
Effect of Ac.ex. on 
appetite is mainly on 
M, F need both  ↑ 
energy expenditure and  
↓ intake 
Balaguera-
Cortes et al., 
2011, [125] 
Cross-over 
randomised 
control 
10 M, young (21.3 
±1.4yr); leans BMI  
(23.7±2.0) 
Acute 3 groups: AE (running, 
VO2= 70%), RT (45ms, 3 
sets of 12 repetitions) , C; 
used energy intake 
↔ food 
intake 
↓ Ghrelin (RT) 
↑ PP (AE &RT) 
↔ PYY 
↑ insulin 
Positive effects of both 
AE & RT; However, 
AE has better long term 
effect on energy 
balance 
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Jones et al., 
2009, [132] 
longitudinal 
study 
12, adolescents & adults; 
overweight/obese; BMI  
(31.8±0.4) 
Chronic 32 wks, 3 times/wk free choice 
of AE, VO2= 60-85% 
- ↔ Ghrelin 
↑ PYY 
Weak positive effect of 
AE on satiety  but was 
limited to a specific age 
group; did not compare 
AE to RT 
Martins et al., 
2010, [131] 
longitudinal 
study 
22 but 15 completed 
(M8, F7); adults (36.9 
±8.3yr); leans BMI  
(31.3±3.3) 
Chronic 12 wks, supervised AE 
(walking or running, five 
times/wk, 75% mxHR; used 
VAS; blood was taken fasting, 
pre- and post intervention 
↑ Hunger; 
↓ Fullness 
↑ Ghrelin 
↔ PYY, GLP-1 
↓ insulin 
 
Small size, conflicting 
results, limited to AE 
Guelfi et al. 
2013, [130] 
longitudinal 
controlled 
study 
33 M; different ages 
(49±7yr); overweight & 
obese BMI  (30.8±4.2) 
Chronic 12 wks, 3 times/wk; 3 groups: 
AE(n=12), RT(n=13), C(n=8); 
AE (cycling), blood was taken 
10 hrs after fasting and at the 
end 
↑ Fullness 
(in AE) 
 
↔ in appetite 
hormones 
↓ leptin 
Limited to men, used a 
liquid caloric diet and 
not a mixed one 
(Abbreviations: Ac.ex., acute exercise; AE, Aerobic Exercise; BMI, body mass index; C, control; Ex., exercise; F, female; GLP-1, glucose like-peptide-1; M, male;  
mins, minutes; mxHR, maximum heart rate; N/A, not applicable or mentioned; PYY, polypeptide YY (peptide tyrosin tyrosine); PP, pancreatic polypeptide; RT, 
Resistance Training; wks, weeks; Visual analogue scale, VAS; VO2, measured maximum oxygen uptake; yr, year.) 
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1.4.4 Aims and hypothesis 
The long term effects of exercise on body homeostasis vary according to the exercise 
type, duration and intensity/volume, as well as characteristics of the studied 
participants. It is also suggested that exercise increases energy expenditure, but this 
effect alone may not be sufficient to achieve the intended goals of exercise on body 
weight as it is thought that regular exercise alone may increase appetite, and therefore 
it must be combined with dietary restriction if weight loss is the desired outcome. 
These concerns have triggered a growing interest in exploring the effects of 
supervised exercise interventions on food intake and appetite. To measure the effects 
of exercise on appetite, several methods were used including measurements of plasma 
concentrations of several appetite stimulating and/or suppressing gut-derived 
hormones.  
Based on the current review of the literature, nine studies were recently 
published on the effects of acute (n=6) or chronic (n=3) exercise on appetite and 
appetite-regulating hormones in participants who were not under energy restricted 
dietary regimes. However, these few studies had their own limitations and some 
conflicting results. Overall, the study protocols were inconsistent and therefore it is 
quite difficult to compare results (Table 1.1.). Limitations also included the fact that 
the majority of studies involved males only, or certain age group or lean participants. 
This has indicated the need for further research that bridges this gap in the published 
literature by overcoming the limitations of the previous works on the effects of 
chronic exercise on appetite and appetite regulating hormones, including the 
enrolment of both men and women and using a mix of measures that assess the long 
term effects of various modes of exercise on appetite. 
Thus, the current longitudinal randomised controlled study aims to investigate 
the effects of different doses of chronic aerobic exercise and progressive resistance 
training on appetite and appetite regulating hormones in previously sedentary 
overweight, or obese males and females who are not under a prescribed regime of 
energy restriction. Based on the currently available literature, it is hypothesised that 
long term structured exercise will not increase subjective feelings of hunger and may 
increase subjective feelings of fullness, as measured with the Electronic Appetite 
Rating System. It is also hypothesised that the subjective appetite alterations will be 
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accompanied by a decrease or no change in the plasma concentrations of the appetite-
stimulating hormone ghrelin, and an increase or no change in the concentrations of the 
satiety hormone PYY.  
Insights from this study could help in improving prescriptions for exercise in 
future strategies for weight management in overweight and obese men and women. 
The expected findings may also influence dietary advice that is given to overweight or 
obese participants embarking on exercise regimes for health and weight management 
based on the effects of different types of exercise on appetite and potentially 
subsequently on food intake. Such information will help the concerned professional in 
prescribing the best dietary advice regarding the necessity for food restriction based 
on scientific evidence.  
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2 Methods 
2.1  Overview 
A longitudinal randomised controlled pilot trial was designed to assess the effects of 
various exercise training programs of aerobic and resistance exercise on appetite and 
appetite regulating hormones. The primary outcome of this research was to determine 
the effects of 8-week supervised exercise training programs of different exercise 
intensities, volumes and modalities on appetite and appetite regulating hormones. 
Secondary outcomes were to determine the effects of various interventions on body 
weight and waist circumference. 
The study was conducted at the Boden Institute of Obesity, Nutrition, Exercise 
& Eating Disorders at the University of Sydney in the period September 2012- 
November 2013. The study was approved by the University of Sydney Human 
Research Ethics Committee (Ethics Ref: No 13364). 
Eligible subjects were randomised, via an equally distributed pre-generated list 
(www.randomization.com), to one of four intervention groups or a control group as 
follows:  
i. High-intensity/low energy expenditure aerobic exercise training (HI:LO) 
ii. Low-intensity/high energy expenditure aerobic exercise training (LO:HI) 
iii. Low-intensity/low energy expenditure aerobic exercise training (LO:LO) 
iv. Progressive resistance training (PRT) 
v. Stretching, massage and fit-ball training program (control). 
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(Abbreviations: WC, waist circumference; PYY, peptide tyrosine tyrosine; GP, general practitioner) 
Figure 2-1: Study design and protocol 
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2.2  Participants 
2.2.1 Recruitment and screening 
Potential participants were recruited through university noticeboards, electronic bulletins and 
a departmental clinical trials database. All potential participants who expressed interest in the 
study were subjected to a telephone screening interview by one of the study coordinators, as 
shown in Figure 2.1. During the telephone interview a brief overview of the study was given 
to the potential participant and the importance of consistent commitment to the study was 
stressed. This was followed by administration of a questionnaire that was designed for 
preliminary assessment of the eligibility for enrolment in the study (Appendix 1).  
Potentially eligible participants were sent an information package (Appendix 2) that 
they were requested to read and complete before the testing day. This information pack 
included a screening form to be completed by their general practitioner. The pre-assessment 
instructions included refraining from ingesting food, alcohol or caffeine, or using tobacco 
products the night before and morning of testing, fasting at least 12 hours prior to testing, 
consumption of an adequate meal the night before testing, and ample fluid (water) 
consumption over the 24-hour period preceding the test to ensure adequate hydration. 
Participants were also requested to use 3-day physical activity questionnaire (Appendix 3) 
[147] and a 3-day food diary (Appendix 4) [147] prior to testing and to avoid significant 
exertion or exercise on the day before and the day of testing. They were also asked to come in 
light clothing appropriate for exercise and the application of electrodes on their chest wall. 
Those on regular medications were requested to follow their normal medication regimen. 
Immediately prior to commencement of testing, participants were screened for 
absolute or relative contraindications to exercise according to the American College of Sports 
Medicine Guidelines for Exercise Testing and Prescription, 2010 [148] 
2.2.2  Eligibility criteria  
2.2.2.1  Inclusion criteria (eligible) 
Potentially eligible participants included those people who were overweight or obese (BMI ≥  
25 kg/m2), aged ≥ 29 ≤ 59 years, were not on lipid lowering medication, had no past history 
of unstable disease, no hypertension and who were currently undertaking less than 3 
structured exercise sessions per week.  
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2.2.2.2  Exclusion criteria (ineligible) 
Participants who were considered ineligible for enrolment included those of BMI (<25 kg/m2) 
and/or had terminal/rapidly progressing illness, amputation, currently doing resistance/aerobic 
exercise > 3 sessions/week, were taking prescribed lipid lowering medications, had any 
musculoskeletal, neuromuscular, or cardiac condition, or any signs or symptoms of unstable 
disease. In addition, all of those who were unable to sit and exercise on a stationary exercise 
bike for up to 45 minutes were excluded. Also, pregnant females and those who showed 
unwillingness to be randomised and to come for training/assessments were excluded. Finally, 
participants who were on a regular diet or who had lost > 5 kg in the last 3 months were also 
excluded. 
2.3 Baseline testing 
On arrival at our institute for baseline testing, participants were verbally briefed about the 
study design and protocols. Any questions were answered and an informed written consent 
form was then signed by the participant. Blood pressure and resting heart rate were measured. 
Anthropometric measurements (height and weight) were then taken as shown in Figure 2.1. 
Height was measured to the nearest 0.1 cm using a wall fixed stadiometer (Tanita, Arlington 
Heights, Illinois, USA). BMI was then calculated by dividing the body weight (in kg) by 
height (in m2).  Overweight was defined as a BMI of 25-30 kg/m2 and obesity as BMI of > 30 
kg/m2 [4]. Waist circumference was measured in the standing position at the smallest 
circumference between the rib margin and iliac crest [149]. Fasting appetite assessment using 
the Electronic Appetite Rating Systems was done as described below [144]. Then a fasting 
blood sample was collected for determination of plasma ghrelin and PYY concentrations. The 
participants’ 3-day physical activity questionnaire [147] (Appendix 3) and 3-day food dairy 
were also collected. All of these baseline tests were repeated at the end of the 8-week study, 
as shown in Figure 2.1. 
Once all initial baseline testing was completed, participants were given a sealed 
envelope containing randomized group allocation to one of the four exercise intervention 
groups or the control group. All of the initial assessments were thus completed with both the 
participants and the investigators blinded to the group allocation. 
2.4   Fasting appetite assessment 
Appetite level was assessed in the fasted state using the Electronic Appetite Ratings System, 
which is a validated electronic version of the visual analogue scale (VAS) [144]. The 
Electronic Appetite Ratings System is a software program that presents questions about 
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appetite on the screen and participants are asked to read the question and then use the arrow 
keys to move a centred vertical cursor along a horizontal line. Once the cursor is in the chosen 
position, the participants were instructed to press ‘continue’, and then confirm their response 
[144]. Questions and anchored responses were: 1) How hungry do you feel now? 2) How full 
do you feel now? 3) How strong is your desire to eat? 4) How much food could you eat now? 
5) How nauseous do you feel now? 6) How satisfied do you feel now? 7) How tired do you 
feel now?  
2.5  Blood sample collection, storage and analysis for 
plasma ghrelin and PYY  
Blood was collected from a suitable antecubital vein into a pre-chilled tube containing 
K2EDTA as an anticoagulant (Becton Dickinson, Franklin Lakes, NJ, USA). The samples 
were kept on ice and then centrifuged at 1100g for 10 minutes at 4°C.  The plasma 
supernatant was then aliquot within 30 minutes into two storage tubes (Sarstedt AG & Co, 
Nümbrecht, Germany) and stored at −80°C until subsequent analysis of plasma total ghrelin 
and total PYY concentrations by radioimmunoassay using commercially available kits 
(GHRT-89HK and PYYT-66HK), Merck Millipore, Billerica, MA, USA) in accordance with 
the manufacturer’s instructions. Blood samples were collected at baseline and at week 8, and 
were always collected at the same time of day. 
2.6 Exercise Protocols 
2.6.1  Exercise test 
Prior to commencement of exercise on the day of baseline testing, cardiorespiratory fitness 
and work capacity changes in cardiorespiratory fitness were assessed via a graded maximal 
exercise test to volitional fatigue to assess VO2 max on the electronically braked cycle 
ergometer (Figure 2.1.).  This test was conducted by an Exercise Physiologist and supervised 
by a study physician, and VO2 max was used to design the training programs. VO2 max was 
assessed as per previous publications [130-132]. Heart rate, ratings of perceived exertion, 
blood pressure and ECG were obtained during each stage [147]. 
2.6.2 Exercise training groups 
2.6.2.1 Aerobic groups 
2.6.2.1.1  High-intensity/low energy expenditure aerobic exercise 
training (HI:LO)  
Participants in the HI:LO group progressed from cycling for 30 minutes at 60% peak aerobic 
capacity (VO2 peak) in weeks 1 and 2 to 45 minutes at a high intensity (70% VO2 peak) in weeks 
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3-8 on a cycle ergometer for two supervised sessions per week. They also undertook one 
additional session of brisk walking on their own each week, at the same intensity and 
duration. Participants performed a 3-minute warm up and cool down at 30W. 
2.6.2.1.2 Low-intensity/high energy expenditure aerobic exercise 
training (LO:HI) 
In the LO:HI group, participants progressed from cycling for 45 minutes in weeks 1 and 2 to 
60 minutes in week 3-8 on a cycle ergometer at a low intensity (50% of peak aerobic capacity 
(VO2peak), for three supervised sessions per week. They also undertook one additional session 
of brisk walking on their own each week, at the same intensity and duration. Participants 
performed a 3-minute warm up and cool down at 30W. 
2.6.2.1.3  Low-intensity/low energy expenditure aerobic exercise 
training (LO:LO) 
In the LO:LO group, participants progressed from cycling for 30 minutes in weeks 1 and 2 to 
45 minutes in weeks 3-8 on a cycle ergometer at a low intensity (50% of peak aerobic 
capacity (VO2peak) for two supervised sessions per week. They also undertook one additional 
session of brisk walking on their own each week at the same intensity and duration. 
Participants performed a 3-minute warm up and cool down at 30W.  
2.6.2.2 Progressive Resistance training group (PRT) 
Participants randomized to the PRT group performed 30 to 45 minutes of progressive 
resistance training three times weekly. All training sessions were supervised and involved 1-3 
sets, 8-12 repetitions at 80-85% of one repetition maximum, in accordance with current 
American College of Sports Medicine guidelines. Exercises were seated leg press, lying chest 
press, lateral pull-down, triceps push down, lunges, shoulder press, seated row, calf raises 
bicep curls and abdominal crunches. The total duration of the session was 40 to 55 minutes, 
which included a 5-minute warm up and cool down at approximately 60% of maximum heart 
rate on a cycle ergometer.  
2.6.3 Control group  
Participants in the control group were prescribed a stretch, massage and fitball protocol, 
designed to elicit no cardiometabolic improvements. Training sessions were home based with 
one visit per fortnight to receive a program update and cycle at a sub-training load for 5-10 
minutes to maintain familiarity with the bike.  
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2.7  Data Analysis 
Data were entered in an Excel file and were exported to Statistical Package for Social 
Scientists version 20 (IBM, New York, USA) for statistical analysis. Quality control for the 
entered data was done before analysis. The central tendencies for continuous variables are 
expressed as mean ± SEM. A test for normality of distribution of the quantitative variables 
was conducted to decide upon appropriate statistical analyses. As normality was assured, 
parametric tests were applied on the quantitative variables (age, weight, BMI, waist 
circumference and circulating appetite regulating hormone concentrations). The baseline 
anthropometric measurements in the various study groups were analysed according to the type 
of exercise training intervention using ANOVA. For all other parameters, non parametric tests 
were adopted i.e. for variables in the Electronic Appetite Ratings System. To test significance 
of the changes after intervention, Paired Sample t test was used for continuous variables and 
Wilcoxon signed-rank test was used for non parametric variables. Analysis of covariance 
(ANCOVA) was carried out to control for the possible influence of waist circumference at 
base line on its matched measurements after intervention. P values of ≤ 0.05 were accepted as 
being statistically significant.   
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3 Results 
3.1 Demographic characteristics of participants in the 
different study groups 
Participants (n=28) were assigned to one of four exercise training intervention groups 
according to the type of exercise training: High-intensity/low energy expenditure aerobic 
exercise training group (HI:LO), (n=7); Low-intensity/high energy expenditure aerobic 
exercise training group (LO:HI), (n=8);  Low-intensity/low energy expenditure aerobic 
exercise training group (LO:LO), (n=4); Progressive resistance training group (PRT), (n=4); 
in addition to a control group (n=5). 
The overall age of the studied subjects was 46.9 ± 1.8 years. There were a greater 
number of female (n=21) than male participants (n=7). However, there was no statistically 
significant difference in age (48.7±1.8 and 41.7±4.6 years respectively) or BMI (32.5±1.2 
and 35.7±2.7 kg/m2) of females and males at baseline. Similarly, there was no statistically 
significant difference in age (46.8±4.1 and 47.0±2.1 years respectively), or BMI (33.3±1.1 
and 32.5±1.9 kg/m2) between participants in the exercise training groups and the control 
group at baseline. 
There were no statistically significant differences between different groups at baseline 
in weight, BMI or waist circumference. However, participants allocated in the HI:LO group 
had relatively higher weight, BMI and WC measurements than those in other intervention 
groups.  
3.2 Baseline and post-intervention values of 
anthropometric measurements  
There was no change from baseline in body weight or BMI in any exercise group, but there 
was a decrease in waist circumference with the HI:LO and LO:HI interventions, when 
comparing pre- and post-intervention values. However, this change was not statistically 
significant after adjusting for baseline values. Meanwhile, the control group showed slight 
increments in all anthropometric measurements, but these differences were not statistically 
significant.  
When the data were split by gender, similar results were obtained, and only reduction 
in WC showed statistical significance in both men and women (data not shown). 
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For further investigation of the effects of various exercise training intervention 
program on anthropometric measurements in the four intervention groups, the difference 
between the baseline and post-intervention values were analysed in each exercise training 
group separately as well as in the control group. All anthropometric measurements were 
lower after intervention compared to baseline among all the exercise training intervention 
groups; however, its magnitude was not similar among groups (Table 3.1.). Notably, overall 
changes in the WC showed statistical significance among the HI:LO and LO:HI intervention 
groups but not in the LO:LO and PRT groups. ANCOVA was conducted to control for the 
possible impact of the differences in baseline readings of waist circumference on the post-
intervention values. The regression model revealed that post-intervention waist 
circumferences were significantly predicted by the baseline values. Moreover, F test for 
significance of different types of exercise revealed that the overall change due to the 
intervention was not statistically significant after adjusting for the baseline values. 
Table 3-1: Anthropometric measurements at baseline and after 8-week exercise training interventions in 
each of the four study groups and the control group 
Study group Anthropometric 
measurement 
Baseline 
 
Post-intervention Change P 
(HI:LO) Weight (kg) 107.0±7.2 105.6±7.4 -1.4±0.6 0.071 
BMI (kg/m2) 37.1±2.4 36.5±2.4 -0.5±0.2 0.063 
WC (cm) 108.9±5.5 106.3±5.4 -2.5±0.4 0.001 
(LO:HI) Weight (kg) 88.1±4.9 87.0±4.3 -1.1±1.1 0.322 
BMI (kg/m2) 32.0±1.4 32.0±1.2 -0.0±0.6 0.950 
WC (cm) 99.1±4.1 96.7±3.8 -2.4±0.8 0.022 
(LO:LO) Weight (kg) 84.9±7.9 84.8±8.3 -0.1±1.1 0.932 
BMI (kg/m2) 29.5±0.5 29.4±0.8 -0.1±0.4 0.850 
WC (cm) 97.0±4.7 95.4±5.3 -1.6±0.7 0.101 
(PRT) Weight (kg) 89.5±9.9 89.2±9.6 -0.3±0.8 0.732 
BMI (kg/m2) 33.3±3.3 33.1±3.2 -0.1±0.3 0.692 
WC (cm) 100.1±9.0 98.8±8.9 -1.3±1.0 0.292 
Control Weight (kg) 92.7±7.8 93.9+8.8 1.3±1.4 0.392 
BMI (kg/m2) 32.5±1.9 32.9±2.1 0.3±0.5 0.519 
WC (cm) 94.6±3.7 95.9±4.7 1.4±1.5 0.424 
Data are means+SEM at baseline and after intervention. Abbreviations: WC, waist circumference; BMI, body 
mass index; (HI:LO), High-intensity/low energy expenditure aerobic exercise training group; (LO:HI), Low-
intensity/high energy expenditure aerobic exercise training group; (LO:LO), Low-intensity/low energy 
expenditure aerobic exercise training group; (PRT), Progressive resistance training group. 
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3.3 Baseline and post-intervention appetite responses 
as assessed by the Electronic Appetite Ratings 
System (EARS)  
No statistically significant differences in fasting appetite ratings were apparent among the 
studied exercise groups or control group, either pre- or post-intervention (Table 3.2). 
Table 3-2: Appetite ratings at baseline and after 8-week exercise training interventions in each of the four 
study groups and the control group 
Study group Appetite responses Baseline Post-intervention P 
 (HI:LO)  Hunger 36.8±10.6 42.3±8.5 0.726 
Fullness 16.8±8.9 28.0±10.1 0.401 
Desire to eat 40.8±5.5 36.3±10.6 0.696 
Prospective consumption 44.3±12.3 39.8±9.9 0.565 
 (LO:HI) Hunger 47.8±16.1 49.0±17.9 0.914 
Fullness 26.5±16.4 24.3±14.1 0.587 
Desire to eat 62.0±5.1 66.8±13.7 0.715 
Prospective consumption 54.3±4.3 54.3±6.4 1.000 
 (LO:LO) Hunger 30.3±25.8 38.3±31.1 0.339 
Fullness 37.7±20.8 5.7±5.6 0.192 
Desire to eat 35.7±20.2 47.3±27.9 0.398 
Prospective consumption 28.0+11.4 58.7+21.2 0.119 
 (PRT) Hunger 41.8+12.7 35.8+18.3 0.600 
Fullness 16.8±7.4 29.3±17.0 0.303 
Desire to eat 49.0±14.4 42.5±15.6 0.423 
Prospective consumption 46.5±8.8 42.3±15.0 0.599 
Control  Hunger 31.3±23.2 65.5±17.7 0.149 
Fullness 25.8±17.5 8.5±3.1 0.374 
Desire to eat 40.3±22.3 67.5±18.6 0.245 
Prospective consumption 41.8±21.1 79.5±7.0 0.076 
Data are represented as mean+SEM. Abbreviations: (HI:LO), High-intensity/low energy expenditure aerobic 
exercise training group; (LO:HI), Low-intensity/high energy expenditure aerobic exercise training group; 
(LO:LO), Low-intensity/low energy expenditure aerobic exercise training group; (PRT), Progressive resistance 
training group. 
3.4 Plasma concentrations of ghrelin at baseline and 
after interventions 
Table 3.3. demonstrates the values of plasma circulating ghrelin levels before and after the 
various interventions among the four study groups compared to controls. There was no 
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statistically significant effect of any type or intensity of exercise on the mean post-
intervention concentrations of circulating ghrelin.  
Table 3-3: Plasma concentrations of ghrelin (pg/ml) at baseline and after 8-week exercise training 
interventions in the four study groups and the control group. 
Study group Baseline Post-intervention Change P 
(HI:LO) 1306±90 1121±83 -185±118 0.17 
(LO:HI) 1624±282 1671±254 47±105 0.67 
(LO:LO) 1725±177 1689±281 -36±119 0.78 
(PRT) 2286±152 2202±47 -84±164 0.64 
Control 1546±223 1457±287 -89±118 0.49 
Data are represented as mean+SEM. Abbreviations: (HI:LO), High-intensity/low energy expenditure aerobic 
exercise training group; (LO:HI), Low-intensity/high energy expenditure aerobic exercise training group; 
(LO:LO), Low-intensity/low energy expenditure aerobic exercise training group; (PRT), Progressive resistance 
training group. 
3.5 Plasma concentrations of PYY at baseline and after 
interventions 
Table 3.4 demonstrates values of plasma PYY levels before and after the various 
interventions among the four study groups compared to controls. There was no statistically 
significant effect of any type or intensity of exercise on the mean post-intervention 
concentrations of circulating PYY. 
Table 3-4: Plasma concentrations of PYY hormone (pg/ml) at baseline and after 8-week exercise training 
interventions in the four study groups and the control group. 
Study group Baseline Post-intervention Change P 
(HI:LO) 403±64 412±58 9±6 0.88 
(LO:HI) 312±24 352±32 40±18 0.06 
(LO:LO) 419±58 403±67 -16±36 0.68 
(PRT) 431±32 391±52 -40±43 0.42 
Control 388±42 407±83 19±72 0.80 
Data are mean+SEM. Abbreviations: PYY, peptide tyrosine-tyrosine; (HI:LO), High-intensity/low energy 
expenditure aerobic exercise training group; (LO:HI), Low-intensity/high energy expenditure aerobic exercise 
training group; (LO:LO), Low-intensity/low energy expenditure aerobic exercise training group; (PRT), 
Progressive resistance training group. 
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4 Discussion 
The current study indicates that 8-weeks of different doses of supervised aerobic exercise or 
progressive resistance training did not significantly change subjective appetite ratings or 
influence the plasma concentrations of the gut-derived appetite regulating hormones ghrelin 
or PYY in overweight or obese adults that were previously sedentary. Our study did not 
involve concurrent energy restriction, and the mean weight and BMI of participants in all 
groups were not significantly affected by the various exercise training interventions. These 
results are different to what might have been expected based on the results of several acute 
exercise studies that did not involve concurrent energy restriction [124-126, 128-133], which 
indicated reductions in appetite and either decreases in circulating concentrations of the 
appetite-stimulating hormone, ghrelin, and / or increases in circulating concentrations of the 
appetite-reducing hormone, PYY.   
The novelty of the current study is that it is, to our knowledge, the only one that was 
designed as a randomized controlled trial to investigate the long term effects of various modes 
of exercise on subjective appetite, plasma concentrations of the appetite regulating hormones 
ghrelin and PYY, and anthropometric measurements. The majority of the published literature 
on the benefits of exercise on appetite regulation and its relation to weight management 
involved acute exercise i.e. exercise for one day and up to one week. In this regard, six 
randomized controlled trials [124-126, 128, 129, 133] were published since 2007, but they 
were all limited to acute exercise and were designed as crossover studies (Table 1.1.). In 
contrast, only very few studies investigated the effects of exercise over a longer period of 
time, of 12-33 weeks [130-132]. However, these chronic exercise studies were either not 
randomized [130-132], or did not include a control group [132], or were limited to men [130], 
or included only lean subjects [131], or were limited to one type of chronic exercise [132], or 
compared only one mode of aerobic exercise to progressive resistance training [130] (Table 
1.1.). The present study aimed to overcome the limitations of previous studies by 
investigating the chronic effects of various doses of aerobic exercise training and compare it 
to the effects of a progressive resistance training exercise program on subjective appetite and 
the plasma concentrations of two appetite regulating hormones: ghrelin and PYY. 
Additionally, the present randomised controlled trial included overweight or obese men and 
women.  
This study indicated no significant effects of various exercise training programs on 
fasting appetite measures, including the feeling of fasting hunger or fullness, either at baseline 
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or after the interventions. The results from our study are different from that of a similar 
longitudinal uncontrolled study in overweight/obese adolescents [132] that reported increased 
satiety after 32-weeks of one mode of aerobic exercise [132]. However, the age of participants 
(adults in our study versus adolescents), as well as the duration of physical activity (8 weeks 
in our study versus 32 weeks) may have contributed to these discrepant findings. The exercise 
intensity used in this study is similar to the HI:LO group in our study. In the study on 
adolescents, the subjective appetite was not assessed similar to our study [132]. Results in the 
present study are also different from another similar study on the effects of 12-weeks 
supervised aerobic exercise program on 15 overweight/obese adults [131], which showed an 
increased feeling of fasting fullness that was accompanied with an increased level of fasting 
hunger [131]. A more recent longitudinal controlled study investigated the effects of 12-
weeks exercise training program and enrolled 33 men of similar age and BMI to our 
participants. That study indicated an increased feeling of fasting fullness only, but this effect 
was limited to the aerobic exercise group only and not in those doing progressive resistance 
training [130]. Of the six studies investigating effects of acute exercise, three [126, 128, 129] 
reported decreases in the feeling of fasting hunger after acute exercise whereas the remaining 
three studies [124, 125, 133] did not find a significant effect of acute exercise on the feeling 
of hunger in the fasted state. These discrepant findings from acute studies may explain the 
equivocal responses in our present study, as it appears that the effects of aerobic exercise on 
subjective appetite may be short lived. Taken together, three out of four chronic studies 
(including the current one) indicate increases in fasting fullness sensations with chronic 
exercise. However, with such wide variations in study parameters (age of participants, 
exercise modality and intensity, sex or BMI of participants etcetera), it is not possible to draw 
definite conclusions about the effects of chronic exercise on appetite without further 
investigation.  
In addition to subjective appetite, other methods were used in previous studies to 
further investigate effects of exercise on appetite. These methods include measurement of 
food intake [119, 140], and more recently the assessment of gut-derived appetite regulating 
hormone concentrations [129, 130]. The latter was selected in the present study to assess 
appetite control. Our study showed no statistically significant alterations in the circulating 
total ghrelin concentrations before and after the four exercise interventions compared to 
controls. However, the changes in mean concentrations of circulating total ghrelin post-
intervention varied, and a notable trend to decreased ghrelin was observed in the HI:LO 
aerobic exercise group. Two previous studies that investigated chronic effects of AE on 
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ghrelin also indicated no change in the plasma concentrations of acylated or active ghrelin 
[130, 132]. However one of these studies was limited to adolescents [132] and the other to 
only men [131] , unlike our study in adults, which included both sexes. In contrast, another 
study investigating the effects of chronic aerobic exercise demonstrated an increase in the 
circulating concentrations of total and active ghrelin, accompanied by an increase of the 
feeling of fasting hunger [131]. The authors attributed the increase in ghrelin concentration to 
the diet-induced weight loss that was observed in their study, which involved a prescription 
for dietary restriction [131]. In the current study, participants were not prescribed any sort of 
dietary restrictions and did not lose a significant amount of weight, and this may explain the 
lack of change in ghrelin concentrations in response to long term exercise. 
In contrast to the current observation of no effect of chronic exercise of different 
modes and intensities on circulating total ghrelin levels, different findings were reported in 
response to acute exercise. Half of the reviewed studies (Table 1.1) reported decreased ghrelin 
levels in response to acute exercise [125, 126, 128], whereas one study reported increased 
ghrelin levels in females but not in males [123], and two studied reported no change [124, 
129]. Again, previous studies used different protocols for assaying ghrelin concentrations, as 
some measured acylated ghrelin concentrations [126, 130] while other measured total ghrelin 
[124]. In another study both total and acylated ghrelin were assayed [132].  
Similar to plasma ghrelin concentrations, circulating concentrations of total PYY did 
not show statistically significant alterations after the four different exercise interventions. 
These findings correlate well with the results for subjective appetite, which also did not alter 
after any of the exercise interventions. Findings from this study are consistent with that of two 
previous studies that did not show significant changes in plasma PYY concentrations after 
long-term exercise [130, 131]. In contrast, one chronic study showed that total PYY 
concentrations increased in overweight adolescents after 32-weeks of supervised aerobic 
exercise program [132]. Possible reasons for variations in the results of previous studies are 
the differences in study designs, exercise protocols and methods used for the determination of 
plasma PYY concentrations. The total PYY concentration was measured in the present study. 
There is a dearth of information in the literature about the link between the intensity, 
duration and type of exercise and its long-term effects on appetite. In a recent acute exercise 
trial, 15 young men performed two types of acute exercise: rope skipping and bicycle 
ergometer to determine the effects of each of these two modes of exercise on appetite. The 
researchers reported a greater suppression of subjective fasting hunger with rope skipping 
than with the bicycle ergometer [150].  However, the authors attributed that greater acute 
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effect of rope skipping on appetite to its weight bearing effects and not to the exercise 
intensity [150].  In the current study, it appeared that 8-weeks of HI:LO aerobic exercise 
resulted in a notable, but not significant, decrease in plasma ghrelin concentrations, without 
any increase in PYY concentrations. In contrast, the LO:LO and the progressive resistance 
training groups did not demonstrate any such changes in the plasma concentrations of these 
appetite regulating hormones. Taken together, these findings indicate that high intensity 
aerobic exercise, but not progressive resistance training, may reduce subjective appetite and / 
or the appetite-stimulating hormone ghrelin. However, there is still considerable ambiguity 
about the effect of different doses of acute and chronic exercise on subjective appetite and 
appetite hormone concentrations in free-living humans, indicating a need for further research 
in this maturating area of human physiology research. 
Results of the current study show that none of the modes or intensities of long-term 
exercise used in our study had a significant impact on overall body weight or BMI of 
participants, men or women. It is important to note that participants in our study were not 
prescribed concurrent energy restriction. Similar previous studies on the effects of various 
structured chronic exercise training programs on participants who were not on energy intake 
restrictions [130-132] as one study reported significant reductions in all of anthropometric 
measures, percentage of body fat and total fat mass after weeks of aerobic exercise program 
[131]. However, the previous study was limited to lean subjects and may not be compared to 
results, such as ours, that were conducted on overweight/obese subjects where other 
researchers indicated a mild decrease in percent of body fat of 2.2% without associated 
reduction in waist circumference or BMI in a group of 12 adolescents [132]. In the current 
study, such effects were not seen and even the mild effect on waist circumference in two 
aerobic exercise groups: HI:LO and LO:HI disappeared after adjusting for the baseline values 
of waist circumference. Other researchers indicated that the  decline in BMI was observed in 
the aerobic exercise group but not in the progressive resistance training group [130]. Others 
indicated specifically that aerobic exercise is more effective in reducing the visceral adipose 
tissue (VAT) content/volume than progressive resistance training that failed to induce VAT 
reduction [50]. However, progressive resistance training was more related to improving 
muscle strength and endurance as well as decreasing the metabolic risk factors including type 
2 diabetes mellitus and dyslipidaemia [15, 19].  
The present study is a pilot study and therefore, one of its limitations is that it included 
relatively small numbers in each group. This may be avoided in future studies, because the 
current work has provided preliminary data that can be used in sample size calculations. The 
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predominance of females participants (75%) may be another limitation of the current study, as 
some of the previous studies indicated differences in the hormones levels between men and 
women, particularly in ghrelin concentrations according to the stage of the menstrual cycle 
[127], albeit  in an acute and not in a chronic exercise study. Another limitation is the lack of 
other indirect methods of subjective appetite assessment such as food intake at an ad libitum 
meal, which assesses energy intake and complements other tools of appetite assessment such 
as that used in our study. Also, only two appetite-regulating hormones were assessed and 
perhaps more of these hormones e.g. PP, GLP-1 and CCK could provide greater insight. 
However, the total ghrelin and PYY hormones were selected in the current study as appetite 
regulators as they were widely used in a majority of the previous studies and were therefore 
considered to allow for direct comparisons between findings of the present study and similar 
studies. 
In view of the findings of the current study, larger studies that use more tools of 
appetite assessment are needed. Such future studies should take in consideration the 
established role of physical activity in preventing weight regain, and lack of compliance with 
physical activity prescriptions, as well as unavailability of an effective, safe and licensed 
weight reducing pharmacological agent [112], understanding the role of various types of 
chronic exercise in appetite regulation is crucial in weight management programs and 
subsequent prevention of chronic diseases associated with increasing body weight. Based on 
the growing evidence of the physiological roles of appetite-regulating gut hormones in energy 
homeostasis and food intake, such research should also include concurrent investigation of 
these hormones. A better understanding could lead to more effective exercise prescriptions in 
weight regain prevention programs in those who have lost weight after long-term dietary 
restriction. Indeed, these people are at higher risk of obesity relapse as a result of the observed 
persistent changes in the circulating mediators of appetite including high ghrelin and low 
PYY concentrations that may ultimately stimulate food intake and weight regain [151]. It will 
be interesting to determine whether combining long-term exercise with energy intake 
restrictions will normalise the increased appetite and appetite-stimulating changes in gut-
derived hormones that were reported in that study [151]. The current study showed that none 
of the types and intensities of exercise investigated had any effect on appetite nor on the 
circulating concentrations of appetite regulating gut hormones. This finding could be taken 
into consideration in prescribing and recommending exercise to the general public, because it 
has been shown that some people ‘reward’ themselves for exercise by eating more [152]. 
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In summary, 8-weeks of different intensities and volumes of regular aerobic exercise 
and progressive resistance training did not significantly influence subjective appetite or the 
plasma levels of total ghrelin or PYY of the overweight and obese adults who participated in 
this randomised controlled trial, in contrary to results that might have been expected from 
studies on acute exercise that reported an “aerobic exercise-induced anorexia”. This “no 
change” effect of chronic exercise on appetite as reported in the current study is in contrast in 
some respects to other studies investigating effects of chronic exercise on appetite, albeit in 
non-randomized or uncontrolled studies in people of differing ages, BMIs and sex to those in 
the current study. These discrepant findings, combined with the emerging role of gut-derived 
hormones in the regulation of energy balance, indicate the need for future studies that define 
the potential roles of different modes and intensities of chronic exercise in weight regain 
prevention programs, particularly in those subjects on diet-induced weight loss program who 
have persistent changes in appetite that may ultimately stimulate food intake and obesity 
relapse.  
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Appendix 1 
 
 
 
 
Telephone Screening Form 
 
Date of Telephone call: ____/____/____  Interviewer: ___________________________ 
 
Source of Participant: _________________________ Time Commenced: ___________  
 
I would like to give you a brief overview of how this exercise study is designed. The research 
requires about 8 weeks of consistent commitment from you. At the start of the study you will 
be randomised (like the roll of a dice) into one of five different exercise groups.  
 
The exercise in each group differs in the intensity of exercise you will do as well as the type 
of the exercise you will be asked to complete. Three of these groups will exercise for 30 - 60 
minutes, 2 or 3 times per week for 8 weeks at the Boden Institue of Obesity, Nutrition and 
Exercise, Camperdown (BIONE), or the University of Sydney, Cumberland Campus, 
Lidcome, and have an additional home-based session each week. In one group you will 
perform resistance exercise three times per week at the University of Sydney, Cumberland 
Campus, Lidcome. In another group, you will be instructed to complete a home-based stretch, 
fit ball and massage program and attend one supervised session each fortnight.  
 
We will provide you with an initial health screen and exercise test that will be supervised by 
our study physicians, Professor Ian Caterson, Professor Stephen Colagiuri and Doctor 
Namson Lau at BIONE, Camperdown.  
 
At your initial visit you will be required to undertake a fasting blood test, maximal exercise 
test and complete a variety of lifestyle questionnaires and forms to help to determine your 
eligibility to participate and provide a summary of your current health and fitness status. We 
will also provide you with follow up tests after 8 weeks exercise training to examine the 
effects of this exercise upon your health and fitness. Each of these assessments will be 
conducted at BIONE. You will also be required to undergo a MRI/MRS body scan at 
Northside Medical Imaging in Hornsby before and after the 8 weeks of training.  
 
During your training visits you will be supervised by researchers from the University of 
Sydney.  
 
I will need to ask you some questions to determine whether you are eligible to participate in 
the study. Are you happy to proceed with this screening? 
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If no, why not?        YES   NO    
Name: _____________________________________________________  
 
2.  Phone Number:  h) ____________________    
w) ____________________  
m) ____________________  
3.  Address: ___________________________________________________  
___________________________________________________  
________________________________Post Code: __________ 
 
 
4.  What is your date of birth: ____ / ____ / ____  How old are you now? ___  years 
 
What is your occupation? _____________________________________ 
 
          YES NO 
5.  Do you live in:  a private home     
     A unit       
     Hostel/retirement home    
     Other (specify)     
 
How would you travel to the Northside Medical Imaging (Hornsby)? 
___________________________________________________________  
 
6.  What is your current:  (i) Body weight?  _________ (1 kg = 2.20462262 pounds) 
(ii) Height?   _________ (1 cm = 0.393700787 inches) 
(iii) BMI (kg/m2)? _________ (> 25) 
 
If BMI less than 25, END HERE (If not sure, continue with screening). 
 
Thank you Mr / Mrs ………..……, you are not eligible for this study but if another study 
comes up that is more suitable, may we keep your contact information and call you about it?  
YES   NO    
 
THANK YOU FOR YOUR KIND ASSISTANCE 
 
Time Finished: _____________ 
 
Time Taken to Complete Screening: _____________ 
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Are you being followed for:  High blood pressure    YES   NO    
High cholesterol/TGs   YES   NO    
Diabetes    YES   NO     
 
8.      Would you be able to sit and exercise on a stationary exercise bike for up to 45 minutes? 
   
        YES   NO    
No, why not? __________________________________________________________  
 
9.  Do you take any medications?     YES   NO    
 
Medication Dose Frequency Reason 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Has any of your medication been changed in the last 2 months? YES   NO  
If yes, how? 
Do you have any chronic illnesses or conditions?    YES   NO    
 
Disease Date of Onset/Diagnosis Currently Stable/Controlled? 
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11.  Do you have angina?       YES   NO    
 If yes, when was your last attack?  Date: ____/____/______ 
 How often do the attacks occur? _______________________________ 
 What usually brings on your angina? ____________________________ 
 What is your usual treatment? _________________________________ 
 
12.  Have you ever had a heart attack?     YES   NO    
 If YES, please specify:   Date: ____/____/__________ 
      Hospital: _________________  
 
13.  Have you ever had a cardiac stress test?    YES   NO    
If YES, please specify:   Date: ____/____/__________ 
      Hospital: _________________ 
 
14.  Do you have a terminal or rapidly progressive disease?  YES   NO    
If yes, please specify: 
________________________________________________________________________ 
 
15.  Have you had a blood clot in the lung or leg in the last 6 months?   
YES   NO    
If yes, please give details: ______________________________________________________ 
______________________________________________________ 
 
16. Do you have any other chronic disease which is out of control or has changed rapidly 
in the last 6 months?        YES   NO    
If yes, please give details: ______________________________________________________ 
______________________________________________________ 
17.  Have you had an amputation?    YES   NO   
If yes, please give details: ____________________________________________________ 
 
 
18. Have you had a fracture in the past 6 months?   YES   NO    
If yes, please give details: ____________________________________________________ 
____________________________________________________ 
19.  Do you currently participate in any exercise? If yes, please describe?  
YES       NO   
Type Times Per 
Week 
Duration/Session Intensity 
(How Hard?) 
How long have you 
been doing this? 
Walking/jogging     
Cycling     
  80 
Swimming/ Aqua 
aerobics 
    
Weight Lifting     
Stretching or 
Gentle exercise 
    
Aerobics Classes     
Dancing     
Other (describe)     
Exercise > 3/7= ineligible;  Exercise 2-3/7= use discretion; Exercise 1/7= eligible 
Comments: ________________________________________________________________ 
________________________________________________________________ 
 
20.  Do you smoke / quit smoking in the last 6 months?   YES   NO    
If yes,  How many cigarettes would you smoke a day?   ____________ 
 What type and brand of cigarette do you smoke?  __________________ 
 
21.  Do you drink alcohol and if so, how much?  _________ YES   NO    
 
22.  Are you pregnant, lactating or have you recently given birth? YES          NO  
 UNSURE  
 
23.  Are you currently participating in any other research studies? YES   NO    
If yes,  What are they? ___________________________________________________ 
Frequency:  ___________________________________________________ 
Time:   ___________________________________________________ 
Type:   ___________________________________________________ 
 
If accepted for this study, are you willing to be randomised to one of five groups exercising 3-
4 days per week for 8 weeks:  
• Low intensity/ low energy expenditure aerobic exercise training on an exercise bike 
• Low intensity/ high energy expenditure aerobic exercise training on an exercise bike 
• High intensity/ low energy expenditure aerobic exercise training on an exercise bike 
• Progressive resistance training 
• Stretching, fit ball and self-massage at home?  
YES   NO    
If no, why not?________________________________________________________ 
 
25.  Are you willing to:  
a) Attend an initial screening and tests before participation at BIONE during weeks 1 
and 8 of the study?  
b) Attend Northside Medical Imaging for MRI/MRS body scans during weeks 1 and 
8 of the study?  
  81 
c) Come to BIONE, or the University of Sydney Cumberland Campus, to undertake 
training 2-3 times a week for 8 weeks  
 
YES   NO    
If no, why? __________________________________________________________ 
 
If yes, would transportation be difficult for you?    YES   NO    
Explain transport needs:
 __________________________________________________________________ 
 
Thank you for answering all of these questions. The chief investigator of the study is Dr 
Nathan Johnson. He will review this questionnaire and we will notify you as whether 
you are eligible for further screening for this study. Do you have any further questions 
about the study?  
 
Comments:  
___________________________________________________________________________
_____________________________________________________________________ 
 
 
Time Finished: _________________ 
Time Taken to Complete Telephone Screening: ____________________________ 
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DAY 1 
A) Details: 
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DAY 3 
A) Details: 
Date: 
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Appendix 4 
Food Record 
 
   
 
 
Name__________________________ Participant Code: ___ ___ ___ ___ 
Date of Birth: _______________ 
Height_________ cm 
Weight at start of diary_____ kg & at end of diary_____ kg 
Contact telephone: __________________ 
Email:  ________________________________________ 
Started Diary on __/__/_____ and Finished on __/__/_____ 
  97 
 
  98 
 
  99 
DAY One Date: ___/___/______, Day of the Week: ___________, Weight (morning):_______kg 
M
ea
l 
Time  Food Eaten  Drinks 
Description 
eg. Weetbix 
Quantity 
eg. 3 biscuits 
Description 
eg. Coke Cola 
Quantity 
eg. 600mls 
Br
ea
kf
as
t 
      
 _______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
__________ 
___________
___________
___________
___________
___________
___________
___________
___________
___________
___________ 
_____________
_____________
_____________
_____________
_____________
_____________
_____________
_____________
_____________
_____________ 
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________ 
Sn
ac
ks
 
   
 _______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
______ 
___________
___________
___________
___________
___________
___________ 
_____________
_____________
_____________
_____________
_____________
_____________ 
__________
__________
__________
__________
__________
__________ 
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DAY One Date: ___/___/______, Day of the Week: ___________, Weight (morning):_______kg 
M
ea
l 
Time  Food Eaten  Drinks 
Description 
eg. Weetbix 
Quantity 
eg. 3 biscuits 
Description 
eg. Coke Cola 
Quantity 
eg. 600mls 
Lu
nc
h 
    
 ________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
_____________ 
 
________
________
________
________
________
________
________
________
________
________
________
________
________ 
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________
__________ 
_______
_______
_______
_______
_______
_______
_______
_______
_______
_______
_______
_______
_______ 
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DAY One Date: ___/___/______, Day of the Week: ___________, Weight (morning):_______kg 
M
ea
l 
Time  Food Eaten  Drinks 
Description 
eg. Weetbix 
Quantity 
eg. 3 biscuits 
Description 
eg. Coke Cola 
Quantity 
eg. 600mls 
Sn
ac
ks
 
      
 _______________________________
_______________________________
_______________________________
___________________________ 
___________
___________
___________
_________ 
_____________
_____________
_____________
_____________ 
__________
__________
__________ 
 
D
in
ne
r 
     
 _______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
_______________________________
________________ 
___________
___________
___________
___________
___________
___________
___________ 
_____________
_____________
_____________
_____________
_____________
_____________
_____________
________ 
__________
__________
__________
__________
__________
__________
______ 
Su
pp
er
/ d
es
se
rt
 
  
 _______________________________
_______________________________
_______________________________
__ 
 
___________
___________
___________
__ 
_____________
_____________
_____________
______ 
__________
__________
__________ 
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Physical Activity:  - TYPE: _________________  Intensity (1-10)_____ 
Duration________min 
Did you drink any alcohol today?  Yes   No  
If yes how much? (eg 3 schooners of beer)  __________________________________ 
Please name any supplements taken and the amount (eg, 1 multivitamin)  
____________________________________________________________________ 
Is today different to your usual routine? If so please briefly describe 
_____________________________________________________________________
_____________________________________________________________________
__________________________________________________________________ 
 
 
